284 results on '"M. Almela"'
Search Results
2. 265. Afectación del bazo en la endocarditis infecciosa: Un enemigo silencioso
- Author
-
E. Quintana, X. Castañeda, A. Del Río, A. Moreno, J.M. Pericás, C. Falces, J. Ramírez, M. Almela, C. Cervera, F. Marco, M. Josa, J.M. Miró, and C.A. Mestres
- Subjects
Medicine ,Surgery ,RD1-811 - Abstract
La endocarditis infecciosa predispone al absceso esplénico, de incidencia mal definida y que aumenta la morbimortalidad. No está estandarizado el momento para esplenectomía cuando se requiere intervención por endocarditis. Se describe la experiencia con endocarditis y patología esplénica asociada e indicación quirúrgica valvular y esplénica. Material y métodos: Revisión retrospectiva de la base de datos prospectiva de endocarditis, definida por criterios modificados de Duke. Análisis de pacientes diagnosticados de infarto/absceso esplénico mediante imagen/estudio post mortem. En los casos de esplenectomía, se practicó en la misma intervención después del procedimiento valvular. Resultados: Entre enero de 1995 – julio de 2011 se recogieron 737 episodios de endocarditis; 62 (8,41%) pacientes presentaron infarto/absceso esplénico con fiebre persistente y dolor abdominal; 6 (8,9%) requirieron esplenectomía; 5 (83%) eran varones. La edad media fue 52 (27–72). EuroSCORE logístico medio fue 37,42% (18,83–60,93%). La endocarditis fue mitral (3), aórtica (2) y multivalvular (mitral y tricúspide). Se aislaron Enterococcus spp (2), Staphylococcus aureus (1), estreptococos del grupo viridans (1), Kingella kingae (1) y hemocultivos negativos (1). El absceso esplénico se diagnosticó por tomografía (4); en 2 la intervención fue urgente, sin imagen. Se practicó sustitución valvular. Tres (50%) fallecieron. En los 6 se confirmó absceso esplénico por histopatología. El seguimiento de los supervivientes a la intervención con esplenectomía fue de 16, 22 y 36 meses, sin recidiva. Conclusiones: Debe sospecharse absceso esplénico en los pacientes con endocarditis, fiebre y dolor abdominal. La esplenectomía y la intervención valvular pueden realizarse en el mismo acto dependiendo de la condición del paciente.
- Published
- 2012
- Full Text
- View/download PDF
3. 269. Veinte años de experiencia con homoinjertos vasculares criopreservados en la infección vascular
- Author
-
E. Quintana, A. Del Río, E. Sandoval, P. Campelos, D. Pereda, A. Moreno, M. Almela, F. Marco, S. Ninot, M. Josa, J. Mulet, J.M. Miró, and C.A. Mestres
- Subjects
Medicine ,Surgery ,RD1-811 - Abstract
La infección vascular es potencialmente letal, afectando a cualquier territorio del aparato circulatorio. Este estudio observacional ofrece datos de seguimiento a largo plazo sobre el comportamiento de los homoinjertos vasculares criopreservados en esta patología. Metodología: Análisis retrospectivo de datos prospectivos de la base de datos departamental. Análisis de supervivencia, reinfección, reintervención y preservación de extremidades. Los pacientes con sospecha clínica de infección vascular fueron tratados mediante sustitución del tejido infectado por homoinjerto vascular criopreservado. Se registraron comorbilidades, indicación quirúrgica y causante microbiológica. Resultados: Desde octubre de 1992 – junio de 2011 se intervinieron 42 pacientes (37 varones, 88%). Edad media 63 ± 11,2. La infección fue primaria (16/38%) y protésica (26/62%). La intervención fue electiva (46%), urgente (33%) y de urgencia vital (21%). Los estafilococos (13/31%), infección polimicrobiana (6/14%) y el cultivo negativo (5/12%) fueron los diagnósticos microbiológicos más frecuentes. En 27 (64%) se implantó un homoinjerto y en 15 (36%) un homoinjerto compuesto. Se implantaron 68 homoinjertos (39 ilíacas, 14 bifurcados, 12 aortas torácicas). Hubo 21 intervenciones sobre el sector aortofemoral (50%). No hubo pérdidas en el seguimiento. La estancia media fue de 30,5 días. Excluyendo la mortalidad hospitalaria (23,8%) el 46,9% falleció durante el seguimiento. La mediana de supervivencia fue 9,9 años (intervalo de confianza [IC] 95%: 3,9–15,9). Hubo 8 reoperaciones por motivos no infecciosos. Durante el seguimiento no hubo reinfecciones vasculares. Conclusiones: Este estudio a largo plazo contribuye a mantener la indicación para el implante de homoinjertos vasculares criopreservados en las infecciones vasculares. Los resultados demuestran un comportamiento satisfactorio en esta población multimórbida.
- Published
- 2012
- Full Text
- View/download PDF
4. Cathepsin W, T-cell receptor-associated transmembrane adapter 1, lymphotactin and killer cell lectin like receptor K1 are sensitive and specific RNA biomarkers of canine epitheliotropic lymphoma
- Author
-
Jadesola Temitope Olayinka, Akanksha Nagarkar, Diana Junyue Ma, Neil B. Wong, Andrew Romasco, Cesar Piedra-Mora, Linda Wrijil, Clement N. David, Heather L. Gardner, Nicholas A. Robinson, Kelly L. Hughes, Bruce Barton, Cheryl A. London, Ramón M. Almela, and Jillian M. Richmond
- Subjects
cutaneous T cell lymphoma (CTCL) ,epitheliotropic lymphoma (EL) ,interface dermatitis (ID) ,dog (canine) ,cathepsin W (CTSW) ,T cell receptor associated transmembrane adaptor 1 (TRAT1) ,Veterinary medicine ,SF600-1100 - Abstract
Cutaneous T-cell lymphoma (CTCL) is an uncommon type of lymphoma involving malignant skin-resident or skin-homing T cells. Canine epitheliotropic lymphoma (EL) is the most common form of CTCL in dogs, and it also spontaneously arises from T lymphocytes in the mucosa and skin. Clinically, it can be difficult to distinguish early-stage CTCLs apart from other forms of benign interface dermatitis (ID) in both dogs and people. Our objective was to identify novel biomarkers that can distinguish EL from other forms of ID, and perform comparative transcriptomics of human CTCL and canine EL. Here, we present a retrospective gene expression study that employed archival tissue from biorepositories. We analyzed a discovery cohort of 6 canines and a validation cohort of 8 canines with EL which occurred spontaneously in client-owned companion dogs. We performed comparative targeted transcriptomics studies using NanoString to assess 160 genes from lesional skin biopsies from the discovery cohort and 800 genes from the validation cohort to identify any significant differences that may reflect oncogenesis and immunopathogenesis. We further sought to determine if gene expression in EL and CTCL are conserved across humans and canines by comparing our data to previously published human datasets. Similar chemokine profiles were observed in dog EL and human CTCL, and analyses were performed to validate potential biomarkers and drivers of disease. In dogs, we found enrichment of T cell gene signatures, with upregulation of IFNG, TNF, PRF1, IL15, CD244, CXCL10, and CCL5 in EL in dogs compared to healthy controls. Importantly, CTSW, TRAT1 and KLRK1 distinguished EL from all other forms of interface dermatitis we studied, providing much-needed biomarkers for the veterinary field. XCL1/XCL2 were also highly specific of EL in our validation cohort. Future studies exploring the oncogenesis of spontaneous lymphomas in companion animals will expand our understanding of these disorders. Biomarkers may be useful for predicting disease prognosis and treatment responses. We plan to use our data to inform future development of targeted therapies, as well as for repurposing drugs for both veterinary and human medicine.
- Published
- 2023
- Full Text
- View/download PDF
5. Pathology in Practice
- Author
-
Riley K, Aronson, David S, Conway, Stephanie A, Pumphrey, Ramón M, Almela, Adam, Powers, Annabelle, Burnum, and Francisco O, Conrado
- Subjects
General Veterinary - Published
- 2022
- Full Text
- View/download PDF
6. Risk scores' performance and their impact on operative decision-making in left-sided endocarditis: a cohort study
- Author
-
A, Fernández-Cisneros, M, Hernández-Meneses, J, Llopis, E, Sandoval, D, Pereda, J, Alcocer, C, Barriuso, M, Castellá, J, Ambrosioni, J M, Pericàs, B, Vidal, C, Falces, C, Ibáñez, J, Perdomo, I, Rovira, C, García-de-la-María, A, Moreno, M, Almela, A, Perisinotti, A, Dahl, P, Castro, J M, Miró, and E, Quintana
- Subjects
Adult ,Cohort Studies ,Endocarditis ,Risk Factors ,Humans ,Endocarditis, Bacterial ,Cardiac Surgical Procedures ,Risk Assessment ,Retrospective Studies - Abstract
The accuracy of contemporary risk scores in predicting perioperative mortality in infective endocarditis (IE) remains controversial. The aim is to evaluate the performance of existent mortality risk scores for cardiovascular surgery in IE and the impact on operability at high-risk thresholds. A single-center retrospective review of adult patients diagnosed with acute left-sided IE undergoing surgery from May 2014 to August 2019 (n = 142) was done. Individualized risk calculation was obtained according to the available mortality risk scores: EuroScore I and II, PALSUSE, Risk-E, Costa, De Feo-Cotrufo, AEPEI, STS-risk, STS-IE, APORTEI, and ICE-PCS scores. A cross-validation analysis was performed on the score with the best area under the curve (AUC). The 30-day survival was 96.5% (95%CI 91-98%). The score with worse area under the curve (AUC = 0.6) was the STS-IE score, while the higher was for the RISK-E score (AUC = 0.89). The AUC of the majority of risk scores suggested acceptable performance; however, statistically significant differences in expected versus observed mortalities were common. The cross-validation analysis showed that a large number of survivors ( 75%) would not have been operated if arbitrary high-risk threshold estimates had been used to deny surgery. The observed mortality in our cohort is significantly lower than is predicted by contemporary risk scores. Despite the reasonable numeric performance of the analyzed scores, their utility in judging the operability of a given patient remains questionable, as demonstrated in the cross-validation analysis. Future guidelines may advise that denial of surgery should only follow a highly experienced Endocarditis Team evaluation.
- Published
- 2022
7. Using Gene Expression Analysis to Understand Complex Autoimmune Skin Disease Patients: A Series of Four Canine Cutaneous Lupus Erythematosus Cases
- Author
-
Alice A. Amudzi, Cesar Piedra-Mora, Diana Junyue Ma, Neil B. Wong, Clement N. David, Nicholas A. Robinson, Ramón M. Almela, and Jillian M. Richmond
- Subjects
General Veterinary ,immune system diseases - Abstract
Cutaneous Lupus Erythematosus (CLE) is an autoimmune skin disease that occurs in almost two-thirds of people with Systemic Lupus Erythematosus (SLE) and can exist as its own entity. Despite its negative impact on the quality of life of patients, lupus pathogenesis is not fully understood. In recent years, the role of gene expression analysis has become important in understanding cellular functions and disease causation within and across species. Interestingly, dogs also develop CLE, providing a spontaneous animal model of disease. Here, we present a targeted transcriptomic analysis of skin biopsies from a case series of four dogs with complex autoimmunity with suspected CLE. We identified 92 differentially expressed genes (DEGs), including type 1 interferon, B cell, and T cell-related genes, in the four cases compared to healthy skin margin controls. Additionally, we compared our results with existing CLE datasets from humans and mice and found that humans and canines share 49 DEGs, whereas humans and mice shared only 25 DEGs in our gene set. Immunohistochemistry of IFNG and CXCL10, two of the most highly upregulated inflammatory mediators, confirmed protein-level expression and revealed immune cells as the primary source of CXCL10 in dogs with SLE, whereas keratinocytes stained strongly for CXCL10 in dogs without SLE. We propose that gene expression analysis may aid the diagnosis of complex autoimmune skin diseases and that dogs may provide important insights into CLE and SLE pathogeneses, or more broadly, skin manifestations during systemic autoimmunity.
- Published
- 2021
8. Gene Expression Analysis in Four Dogs With Canine Pemphigus Clinical Subtypes Reveals B Cell Signatures and Immune Activation Pathways Similar to Human Disease
- Author
-
Ramón M. Almela, Diana Junyue Ma, Haya S. Raef, Nicholas A. Robinson, Cesar Piedra-Mora, Jillian M. Richmond, Neil B. Wong, and Clément N. David
- Subjects
Pemphigoid ,Medicine (General) ,skin ,Mucocutaneous zone ,Biology ,CD19 ,Immune system ,R5-920 ,immune system diseases ,medicine ,NanoString ,cytokine ,CXCL10 ,skin and connective tissue diseases ,B cell ,comparative immunology ,integumentary system ,Acantholysis ,autoimmune blistering diseases ,pemphigus ,General Medicine ,Brief Research Report ,medicine.disease ,canine (dog) ,Pemphigus ,medicine.anatomical_structure ,Immunology ,biology.protein ,gene expression ,Medicine - Abstract
Pemphigus is a group of autoimmune-mediated mucocutaneous blistering diseases characterized by acantholysis. Pemphigus has also been recognized in dogs and shares similar clinical characteristics and variants with human pemphigus. While relationships between human and canine pemphigus have been reported, gene expression patterns across species have not been described in the literature. We sought to perform gene expression analysis of lesional skin tissue from four dogs with various forms of pemphigus to examine gene expression during spontaneous disease in dogs. We found increased T and B cell signatures in canine pemphigus lesions compared to controls, as well as significant upregulation ofCCL3, CCL4, CXCL10, andCXCL8 (IL8), among other genes. Similar chemokine/cytokine expression patterns and immune infiltrates have been reported in humans, suggesting that these genes play a role in spontaneous disease. Direct comparison of our dataset to previously published human pemphigus datasets revealed five conserved differentially expressed genes:CD19, WIF1, CXCL10, CD86, andS100A12. Our data expands our understanding of pemphigus and facilitates identification of biomarkers for prediction of disease prognosis and treatment response, which may be useful for future veterinary and human clinical trials.
- Published
- 2021
9. Shared inflammatory and skin-specific gene signatures reveal common drivers of discoid lupus erythematosus in canines, humans and mice
- Author
-
Neil B. Wong, Clément N. David, Ramón M. Almela, Colton J. Garelli, Jillian M. Richmond, Linda M. Wrijil, Nicholas A. Robinson, Cesar Piedra-Mora, and Gina Scarglia
- Subjects
Cell type ,Discoid lupus erythematosus ,Canine discoid lupus erythematosus ,Canine (dog) ,Specialties of internal medicine ,Building and Construction ,Disease ,Biology ,medicine.disease ,Transcriptome ,Cutaneous lupus erythematosus ,Immune system ,RC581-951 ,Chemokine ,Immunology ,medicine ,Discoid lupus ,Gene family ,CXCL10 ,Electrical and Electronic Engineering ,Cytokine ,Skin - Abstract
Autoimmune skin diseases are complex and are thought to arise from a combination of genetics and environmental exposures, which trigger an ongoing immune response against self-antigens. Companion animals including cats and dogs are known to develop inflammatory skin conditions similar to humans and share the same environment, providing opportunities to study spontaneous disease that encompasses genetic and environmental factors with a One Health approach. A strength of comparative immunology approaches is that immune profiles may be assessed across different species to better identify shared or conserved pathways that might drive inflammation. Here, we performed a comparative study of skin from canine discoid lupus erythematosus (DLE) using NanoString nCounter technology. We compared these gene expression patterns to those of human DLE and a mouse model of cutaneous lupus. We found strong interferon signatures, with CXCL10, ISG15, and an S100 gene family member among the highest, most significant DEGs upregulated across species. Cell type analysis revealed marked T-cell and B-cell infiltration. Interestingly, canine DLE samples also recapitulated downregulated skin homeostatic genes observed in human DLE. We conclude that spontaneous DLE in dogs captures many features that are present in human disease and may serve as a more complete model for conducting further genomic and/or transcriptomic studies.
- Published
- 2020
10. Efficacy and safety of fosfomycin plus imipenem versus vancomycin for complicated bacteraemia and endocarditis due to methicillin-resistant Staphylococcus aureus: a randomized clinical trial
- Author
-
J.M. Pericàs, A. Moreno, M. Almela, C. García-de-la-Mària, F. Marco, P. Muñoz, C. Peña, A. de Alarcón, A. del Río, A. Eworo, A. Cruceta, J.C. Paré, C.A. Mestres, J.M. Miró, José M. Miró, Asunción Moreno, Juan M. Pericàs, Juan Ambrosioni, Adrián Tellez, Marta Hernandez-Meneses, Ana del Río, Carlos Cervera, Francesc Marco, Cristina Garcia de la Mària, Yolanda Armero, Manel Almela, Carlos A. Mestres, Juan C. Paré, David Fuster, Ramón Cartañá, Salvador Ninot, Manel Azqueta, Marta Sitges, Jose Ramírez, Merce Brunet, Dolors Soy, Jaume Llopis, Carmen Peña, Oriol Gasch, Cristina Suarez, Miquel Pujol, Javier Ariza, Jordi Carratalà, Francisco Gudiol, Patricia Muñoz, Alia Eworo, Emilio Bouza, Arístides de Alarcón, Mercè Gurgui, Natividad Benito, Juan-Emilio Losa-Garcia, Enrique Navas, Jose R. Paño-Pardo, Belén Loeches, Jose R. Arribas, Miguel Montejo, Juan Galvez, University of Zurich, Moreno, A, Ministerio de Sanidad y Consumo (España), Instituto de Salud Carlos III, Ministerio de Economía y Competitividad (España), Institut d'Investigacions Biomèdiques August Pi i Sunyer, European Society of Clinical Microbiology and Infectious Diseases, and Federation of European Microbiological Societies
- Subjects
Male ,Methicillin-Resistant Staphylococcus aureus ,0301 basic medicine ,Microbiology (medical) ,medicine.medical_specialty ,Imipenem ,030106 microbiology ,Treatment outcome ,610 Medicine & health ,Bacteremia ,Microbial Sensitivity Tests ,Fosfomycin ,medicine.disease_cause ,2726 Microbiology (medical) ,law.invention ,03 medical and health sciences ,Randomized controlled trial ,Vancomycin ,law ,Internal medicine ,medicine ,Humans ,Endocarditis ,Aged ,Aged, 80 and over ,business.industry ,2725 Infectious Diseases ,General Medicine ,Middle Aged ,medicine.disease ,Methicillin-resistant Staphylococcus aureus ,10020 Clinic for Cardiac Surgery ,Anti-Bacterial Agents ,Treatment Outcome ,Infectious Diseases ,Multicenter study ,Female ,business ,medicine.drug - Abstract
FOSIMI Investigators., This work was supported by the Ministerio de Sanidad y Consumo of Spain (Fondo de Investigaciones Sanitarias, Instituto de Salud Carlos III, Madrid, Spain, Grant #EC0800190). JMP received a “Rio Hortega” Research Grant (CM14/00135; 2015-16) from Instituto de Salud Carlos III and the Ministerio de Economia and Competitividad, Madrid (Spain) and the ESCMID/FEMS Research Fellowship 2016. JMM received a personal 80:20 research grant from the Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, during 2017–19.
- Published
- 2018
- Full Text
- View/download PDF
11. A Review of Immunotherapeutic Strategies in Canine Malignant Melanoma
- Author
-
Agustina Anson and Ramón M. Almela
- Subjects
Oncology ,medicine.medical_specialty ,040301 veterinary sciences ,medicine.medical_treatment ,Genetic enhancement ,review ,canine ,Malignancy ,0403 veterinary science ,Cell therapy ,03 medical and health sciences ,Immune system ,malignant ,Internal medicine ,vaccine ,medicine ,melanoma ,030304 developmental biology ,0303 health sciences ,lcsh:Veterinary medicine ,General Veterinary ,business.industry ,Melanoma ,Translational medicine ,Cancer ,04 agricultural and veterinary sciences ,Immunotherapy ,medicine.disease ,gene therapy ,lcsh:SF600-1100 ,immunotherapy ,business - Abstract
In dogs, melanomas are relatively common tumors and the most common form of oral malignancy. Biological behavior is highly variable, usually aggressive, and frequently metastatic, with reported survival times of three months for oral or mucosal melanomas in advanced disease stages. Classical clinical management remains challenging; thus, novel and more efficacious treatment strategies are needed. Evidence-based medicine supports the role of the immune system to treat neoplastic diseases. Besides, immunotherapy offers the possibility of a precise medicinal approach to treat cancer. In recent years, multiple immunotherapeutic strategies have been developed, and are now recognized as a pillar of treatment. In addition, dogs represent a good model for translational medicine purposes. This review will cover the most relevant immunotherapeutic strategies for the treatment of canine malignant melanoma, divided among five different categories, namely, monoclonal antibodies, nonspecific immunotherapy activated by bacteria, vaccines, gene therapy, and lymphokine-activated killer cell therapy.
- Published
- 2019
12. Clinical presentation, aetiology and outcomes of infective endocarditis. Results of the ESC-EORP EURO-ENDO (European infective endocarditis) registry: a prospective cohort study
- Author
-
Habib G., Erba P. A., Iung B., Donal E., Cosyns B., Laroche C., Popescu B. A., Prendergast B., Tornos P., Sadeghpour A., Oliver L., Vaskelyte J. -J., Sow R., Axler O., Maggioni A. P., Lancellotti P, C P Gale, B Beleslin, A Budaj, O Chioncel, N Dagres, N Danchin, J Emberson, D Erlinge, M Glikson, A Gray, M Kayikcioglu, A P Maggioni, V K Nagy, A Nedoshivin, A-S Petronio, J Roos-Hesselink, L Wallentin, U Zeymer, G Habib, P Lancellotti, B Cosyns, E Donal, P Erba, B Iung, B A Popescu, B Prendergast, P Tornos, M Andarala, C Berle, A Brunel-Lebecq, E Fiorucci, C Laroche, V Missiamenou, C Taylor, N N Ali Tatar-Chentir, M Al-Mallah, M Astrom Aneq, G Athanassopoulos, L P Badano, S Benyoussef, E Calderon Aranda, N M Cardim, K-L Chan, I Cruz, T Edvardsen, G Goliasch, A Hagendorff, K Hristova, O Kamp, D-H Kang, W Kong, S Matskeplishvili, M Meshaal, M Mirocevic, A N Neskovic, M Pazdernik, E Plonska-Gosciniak, M Raissouni, R Ronderos, L E Sade, A Sadeghpour, A Sambola, S Sengupta, J Separovic-Hanzevacki, M Takeuchi, E Tucay, A C Tude Rodrigues, A Varga, J Vaskelyte, K Yamagata, K Yiangou, H Zaky, I Granada, M Mahia, S Ressi, F Nacinovich, A Iribarren, P Fernandez Oses, G Avegliano, E Filipini, R Obregon, M Bangher, J Dho, L Cartasegna, M L Plastino, V Novas, C Shigel, G Reyes, M De Santos, N Gastaldello, M Granillo Fernandez, M Potito, G Streitenberger, P Velazco, J H Casabé, C Cortes, E Guevara, F Salmo, M Seijo, F Weidinger, M Heger, R Brooks, C Stöllberger, C-Y Ho, L Perschy, L Puskas, C Binder, R Rosenhek, M Schneider, M-P Winter, E Hoffer, M Melissopoulou, E Lecoq, D Legrand, S Jacquet, M Massoz, L Pierard, S Marchetta, R Dulgheru, C D Emal, C Oury, S Droogmans, D Kerkhove, D Plein, L Soens, C Weytjens, A Motoc, B Roosens, I Lemoine, I Rodrigus, B Paelinck, B Amsel, P Unger, D Konopnicki, C Beauloye, A Pasquet, J L Vanoverschelde, S Pierard, D Vancraeynest, F Sinnaeve, J L Andrade, K Staszko, R Dos Santos Monteiro, M H Miglioranza, D L Shuha, M Alcantara, V Cravo, L Fazzio, A Felix, M Iso, C Musa, A P Siciliano, F Villaca Filho, A Rodrigues, F Vilela, J Braga, R Silva, D Rodrigues, L Silva, S Morhy, C Fischer, M Vieira, T Afonso, J Abreu, S N Falcao, V A Moises, A Gouvea, F J Mancuso, A C Souza, C Y Silva, G João, C S Abboud, R Bellio de Mattos Barretto, A Ramos, R Arnoni, J E Assef, D J Della Togna, D Le Bihan, L Miglioli, A P Romero Oliveira, R Tadeu Magro Kroll, D Cortez, C L Gelape, M D C Peirira Nunes, T C De Abreu Ferrari, K Hay, V Le, M Page, F Poulin, C Sauve, K Serri, C Mercure, J Beaudoin, P Pibarot, I A Sebag, L G Rudski, G Ricafort, B Barsic, V Krajinovic, M Vargovic, D Lovric, V Reskovic-Luksic, J Vincelj, S Jaksic Jurinjak, V Yiannikourides, M Ioannides, C Pofaides, V Masoura, J Pudich, A Linhart, M Siranec, J Marek, K Blechova, M Kamenik, R Pelouch, Z Coufal, M Mikulica, M Griva, E Jancova, M Mikulcova, M Taborsky, J Precek, M Jecmenova, J Latal, J Widimsky, T Butta, S Machacek, R Vancata, J Spinar, M Holicka, F Pow Chon Long, N Anzules, A Bajana Carpio, G Largacha, E Penaherrera, D Moreira, E Mahfouz, E Elsafty, A Soliman, Y Zayed, J Aboulenein, M Abdel-Hay, A Almaghraby, M Abdelnaby, M Ahmed, B Hammad, Y Saleh, H Zahran, O Elgebaly, A Saad, M Ali, A Zeid, R El Sharkawy, A Al Kholy, R Doss, D Osama, H Rizk, A Elmogy, M Mishriky, P Assayag, S El Hatimi, S Hubert, J-P Casalta, F Gouriet, F Arregle, S Cammilleri, L Tessonnier, A Riberi, E Botelho-Nevers, A Gagneux-Brunon, R Pierrard, C Tulane, S Campisi, J-F Fuzellier, M Detoc, T Mehalla, D Boutoille, A S Lecompte, M Lefebvre, S Pattier, O Al Habash, N Asseray-Madani, C Biron, J Brochard, J Caillon, C Cueff, T Le Tourneau, R Lecomte, M M Magali Michel, J Orain, S Delarue, M Le Bras, J-F Faucher, V Aboyans, A Beeharry, H Durox, M Lacoste, J Magne, D Mohty, A David, V Pradel, V Sierra, A Neykova, B Bettayeb, S Elkentaoui, B Tzvetkov, G Landry, C Strady, K Ainine, S Baumard, C Brasselet, C Tassigny, V Valente-Pires, M Lefranc, B Hoen, B Lefevre, E Curlier, C Callier, N Fourcade, Y Jobic, S Ansard, R Le Berre, F Le Ven, M-C Pouliquen, G Prat, P Le Roux, F Bouchart, A Savoure, C Alarcon, C Chapuzet, I Gueit, C Tribouilloy, Y Bohbot, F Peugnet, M Gun, X Duval, X Lescure, E Ilic-Habensus, N Sadoul, C Selton-Suty, F Alla, F Goehringer, O Huttin, E Chevalier, R Garcia, V Le Marcis, P Tattevin, E Flecher, M Revest, C Chirouze, K Bouiller, L Hustache-Mathieu, T Klopfenstein, J Moreau, D Fournier, A-S Brunel, P Lim, L Oliver, J Ternacle, A Moussafeur, P Chavanet, L Piroth, A Salmon-Rousseau, M Buisson, S Mahy, C Martins, S Gohier, O Axler, F Baumann, S Lebras, C Piper, D Guckel, J Börgermann, D Horstkotte, E Winkelmann, B Brockmeier, D Grey, G Nickenig, R Schueler, C Öztürk, E Stöhr, C Hamm, T Walther, R Brandt, A-C Frühauf, C T Hartung, C Hellner, C Wild, M Becker, S Hamada, W Kaestner, K Stangl, F Knebel, G Baldenhofer, A Brecht, H Dreger, C Isner, F Pfafflin, M Stegemann, R Zahn, B Fraiture, C Kilkowski, A-K Karcher, S Klinger, H Tolksdorf, D Tousoulis, C Aggeli, S Sideris, E Venieri, G Sarri, D Tsiapras, I Armenis, A Koutsiari, G Floros, C Grassos, S Dragasis, L Rallidis, C Varlamos, L Michalis, K Naka, A Bechlioulis, A Kotsia, L Lakkas, K Pappas, C Papadopoulos, S Kiokas, A Lioni, S Misailidou, J Barbetseas, M Bonou, C Kapelios, I Tomprou, K Zerva, A Manolis, E Hamodraka, D Athanasiou, G Haralambidis, H Samaras, L Poulimenos, A Nagy, A Bartykowszki, E Gara, K Mungulmare, R Kasliwal, M Bansal, S Ranjan, A Bhan, M Kyavar, M Maleki, F Noohi Bezanjani, A Alizadehasl, S Boudagh, A Ghavidel, P Moradnejad, H R Pasha, B Ghadrdoost, D Gilon, J Strahilevitz, M Wanounou, S Israel, C d'Agostino, P Colonna, L De Michele, F Fumarola, M Stante, N Marchionni, V Scheggi, B Alterini, S Del Pace, P Stefano, C Sparano, N Ruozi, R Tenaglia, D Muraru, U Limbruno, A Cresti, P Baratta, M Solari, C Giannattasio, A Moreo, B De Chiara, B Lopez Montero, F Musca, C A Orcese, F Panzeri, F Spano, C F Russo, O Alfieri, M De Bonis, S Chiappetta, B Del Forno, M Ripa, P Scarpellini, C Tassan Din, B Castiglioni, R Pasciuta, S Carletti, D Ferrara, M Guffanti, G Iaci, E Lapenna, T Nisi, C Oltolini, E Busnardo, U Pajoro, E Agricola, R Meneghin, D Schiavi, F Piscione, R Citro, R M Benvenga, L Greco, L Soriente, I Radano, C Prota, M Bellino, D Di Vece, F Santini, A Salsano, G M Olivieri, F Turrini, R Messora, S Tondi, A Olaru, V Agnoletto, L Grassi, C Leonardi, S Sansoni, S Del Ponte, G M Actis Dato, A De Martino, N Ohte, S Kikuchi, K Wakami, K Aonuma, Y Seo, T Ishizu, T Machino-Ohtsuka, M Yamamoto, N Iida, H Nakajima, Y Nakagawa, C Izumi, M Amano, M Miyake, K Takahashi, I Shiojima, Y Miyasaka, H Maeba, Y Suwa, N Taniguchi, S Tsujimoto, T Kitai, M Ota, S Yuda, S Sasaki, N Hagiwara, K Yamazaki, K Ashihara, K Arai, C Saitou, S Saitou, G Suzuki, Y Shibata, N Watanabe, S Nishino, K Ashikaga, N Kuriyama, K Mahara, T Okubo, H Fujimaki, H Shitan, H Yamamoto, K Abe, M Terada, S Takanashi, M Sata, H Yamada, K Kusunose, Y Saijo, H Seno, O Yuichiro, T Onishi, F Sera, S Nakatani, H Mizuno, K Sengoku, S W Park, K Eun Kyoung, L Ga Yeon, J-W Hwang, C Jin-Oh, S-J Park, L Sang-Chol, C Sung-A, S Y Jang, R Heo, S Lee, J-M Song, E Jung, J Plisiene, A Dambrauskaite, G Gruodyte, R Jonkaitiene, V Mizariene, J Atkocaityte, R Zvirblyte, R Sow, A Codreanu, T Staub, C Michaux, E C L De la Vega, L Jacobs-Orazi, C Mallia Azzopardi, R G Xuereb, T Piscopo, J Farrugia, M Fenech, E Pllaha, C Vella, D Borg, R Casha, L Grib, E Raevschi, A Grejdieru, D Kravcenco, E Prisacari, E Samohvalov, S Samohvalov, N Sceglova, E Panfile, L Cardaniuc, V Corcea, A Feodorovici, V Gaina, L Girbu, P Jimbei, G Balan, I Cardaniuc, I Benesco, V Marian, N Sumarga, B Bozovic, N Bulatovic, P Lakovic, L Music, R Budde, A Wahadat, T Gamela, T Meijers, J P Van Melle, V M Deursen, H J Crijns, S C Bekkers, E C Cheriex, M Gilbers, B L Kietselaer, C Knackstedt, R Lorusso, S Schalla, S A Streukens, S Chamuleau, M-J Cramer, A Teske, T Van der Spoel, A Wind, J Lokhorst, O Liesbek, H Van Heusden, W Tanis, I Van der Bilt, J Vriend, H De Lange-van Bruggen, E Karijodikoro, R Riezebos, E van Dongen, J Schoep, V Stolk, J T Offstad, J O Beitnes, T Helle-Valle, H Skulstad, R Skardal, N Qamar, S Furnaz, B Ahmed, M H Butt, M F Khanzada, T Saghir, A Wahid, T Hryniewiecki, P Szymanski, K Marzec, M Misztal-Ogonowska, W Kosmala, M Przewlocka-Kosmala, A Rojek, K Woznicka, J Zachwyc, A Lisowska, M Kaminska, J D Kasprzak, E Kowalczyk, D F Strzecka, P Wejner-Mik, M Trabulo, P Freitas, S Ranchordas, G Rodrigues, P Pinto, C Queiros, J Azevedo, L Marques, D Seabra, L Branco, M Cruz, A Galrinho, R Moreira, P Rio, A T Timoteo, M Selas, V Carmelo, B Duque Neves, H Pereira, A Guerra, A Marques, I Pintassilgo, M C Tomescu, N-M Trofenciuc, M Andor, A Bordejevic, H S Branea, F Caruntu, L A Velcean, A Mavrea, M F Onel, T Parvanescu, D Pop, A L Pop-Moldovan, M I Puticiu, L Cirin, I M Citu, C A Cotoraci, D Darabantiu, R Farcas, I Marincu, A Ionac, D Cozma, C Mornos, F Goanta, I Popescu, R Beyer, R Mada, R Rancea, R Tomoaia, H Rosianu, C Stanescu, Z Kobalava, J Karaulova, E Kotova, A Milto, A Pisaryuk, N Povalyaev, M Sorokina, J Alrahimi, A Elshiekh, A Jamiel, A Ahmed, N Attia, B Putnikovic, A Dimic, B Ivanovic, S Matic, D Trifunovic, J Petrovic, D Kosevic, I Stojanovic, I Petrovic, P Dabic, P Milojevic, I Srdanovic, S Susak, L Velicki, A Vulin, M Kovacevic, A Redzek, M Stefanovic, T C Yeo, W Kf Kong, K K Poh, I Vilacosta, C Ferrera, C Olmos, M Abd El-Nasser, F Calvo Iglesias, E Blanco-Gonzalez, M Bravo Amaro, E Lopez-Rodriguez, J Lugo Adan, A N Germinas, P Pazos-Lopez, M Pereira Loureiro, M T Perez, S Raposeiras-Roubin, S Rasheed Yas, M-M Suarez-Varela, F Vasallo Vidal, D Garcia-Dorado, N Fernandez-Hidalgo, T Gonzalez-Alujas, J Lozano, O Maisterra, N Pizzi, R Rios, A Bayes-Genis, L Pedro Botet, N Vallejo, C Llibre, L Mateu, R Nunez, D Quesada, E Berastegui, D Bosch Portell, J Aboal Vinas, X Albert Bertran, R Brugada Tarradellas, P Loma-Osorio Ricon, C Tiron de Llano, M A Arnau, A Bel, M Blanes, A Osa, M Anguita, F Carrasco, J C Castillo, J L Zamorano, J L Moya Mur, M Alvaro, C Fernandez-Golfin, J M Monteagudo, E Navas Elorza, M C Farinas Alvarez, J Aguero Balbin, J Zarauza, J F Gutierrez-Diez, C Arminanzas, F Arnaiz de Las Revillas, A Arnaiz Garcia, M Cobo Belaustegui, M Fernandez Sampedro, M Gutierrez Cuadra, L Garcia Cuello, C Gonzalez Rico, R Rodriguez-Alvarez, J Goikoetxea, M Montejo, J M Miro, M Almela, J Ambrosioni, A Moreno, E Quintana, E Sandoval, A Tellez, J M Tolosana, B Vidal, C Falces, D Fuster, C Garcia-de-la-Maria, M Hernandez-Meneses, J Llopis, F Marco, I Ruiz-Zamora, A Bardaji Ruiz, E Sanz Girgas, G Garcia-Pardo, M Guillen Marzo, A Rodriguez Oviedo, A Villares Jimenez, L Abid, R Hammami, S Kammoun, M S Mourali, F Mghaieth Zghal, M Ben Hlima, S Boudiche, S Ouali, L Zakhama, S Antit, I Slama, O Gulel, M Sahin, E Karacaglar, S Kucukoglu, O Cetinarslan, U Y Sinan, U Canpolat, B Mutlu, H Atas, R Dervishova, C Ileri, J Alhashmi, J Tahir, P Zarger, F Baslib, S Woldman, L Menezes, C Primus, R Uppal, I Bvekerwa, B Chandrasekaran, A Kopanska, J Chambers, J Hancock, J Klein, R Rajani, M P Ursi, S Cannata, R Dworakowski, A Fife, J Breeze, M Browne-Morgan, M Gunning, S Streather, F M Asch, M Zemedkun, B Alyavi, J Uzokov, G., Habib, P. A., Erba, B., Iung, E., Donal, B., Cosyn, C., Laroche, B. A., Popescu, B., Prendergast, P., Torno, A., Sadeghpour, L., Oliver, J. -J., Vaskelyte, R., Sow, O., Axler, A. P., Maggioni, P, Lancellotti, P Gale, C, Beleslin, B, Budaj, A, Chioncel, O, Dagres, N, Danchin, N, Emberson, J, Erlinge, D, Glikson, M, Gray, A, Kayikcioglu, M, P Maggioni, A, K Nagy, V, Nedoshivin, A, Petronio, A-S, Roos-Hesselink, J, Wallentin, L, Zeymer, U, Habib, G, Lancellotti, P, Cosyns, B, Donal, E, Erba, P, Iung, B, A Popescu, B, Prendergast, B, Tornos, P, Andarala, M, Berle, C, Brunel-Lebecq, A, Fiorucci, E, Laroche, C, Missiamenou, V, Taylor, C, N Ali Tatar-Chentir, N, Al-Mallah, M, Astrom Aneq, M, Athanassopoulos, G, P Badano, L, Benyoussef, S, Calderon Aranda, E, M Cardim, N, Chan, K-L, Cruz, I, Edvardsen, T, Goliasch, G, Hagendorff, A, Hristova, K, Kamp, O, Kang, D-H, Kong, W, Matskeplishvili, S, Meshaal, M, Mirocevic, M, N Neskovic, A, Pazdernik, M, Plonska-Gosciniak, E, Raissouni, M, Ronderos, R, E Sade, L, Sadeghpour, A, Sambola, A, Sengupta, S, Separovic-Hanzevacki, J, Takeuchi, M, Tucay, E, C Tude Rodrigues, A, Varga, A, Vaskelyte, J, Yamagata, K, Yiangou, K, Zaky, H, Granada, I, Mahia, M, Ressi, S, Nacinovich, F, Iribarren, A, Fernandez Oses, P, Avegliano, G, Filipini, E, Obregon, R, Bangher, M, Dho, J, Cartasegna, L, L Plastino, M, Novas, V, Shigel, C, Reyes, G, De Santos, M, Gastaldello, N, Granillo Fernandez, M, Potito, M, Streitenberger, G, Velazco, P, H Casabé, J, Cortes, C, Guevara, E, Salmo, F, Seijo, M, Weidinger, F, Heger, M, Brooks, R, Stöllberger, C, Ho, C-Y, Perschy, L, Puskas, L, Binder, C, Rosenhek, R, Schneider, M, Winter, M-P, Hoffer, E, Melissopoulou, M, Lecoq, E, Legrand, D, Jacquet, S, Massoz, M, Pierard, L, Marchetta, S, Dulgheru, R, D Emal, C, Oury, C, Droogmans, S, Kerkhove, D, Plein, D, Soens, L, Weytjens, C, Motoc, A, Roosens, B, Lemoine, I, Rodrigus, I, Paelinck, B, Amsel, B, Unger, P, Konopnicki, D, Beauloye, C, Pasquet, A, L Vanoverschelde, J, Pierard, S, Vancraeynest, D, Sinnaeve, F, L Andrade, J, Staszko, K, Dos Santos Monteiro, R, H Miglioranza, M, L Shuha, D, Alcantara, M, Cravo, V, Fazzio, L, Felix, A, Iso, M, Musa, C, P Siciliano, A, Villaca Filho, F, Rodrigues, A, Vilela, F, Braga, J, Silva, R, Rodrigues, D, Silva, L, Morhy, S, Fischer, C, Vieira, M, Afonso, T, Abreu, J, N Falcao, S, A Moises, V, Gouvea, A, J Mancuso, F, C Souza, A, Y Silva, C, João, G, S Abboud, C, Bellio de Mattos Barretto, R, Ramos, A, Arnoni, R, E Assef, J, J Della Togna, D, Le Bihan, D, Miglioli, L, P Romero Oliveira, A, Tadeu Magro Kroll, R, Cortez, D, L Gelape, C, C Peirira Nunes, M D, C De Abreu Ferrari, T, Hay, K, Le, V, Page, M, Poulin, F, Sauve, C, Serri, K, Mercure, C, Beaudoin, J, Pibarot, P, A Sebag, I, G Rudski, L, Ricafort, G, Barsic, B, Krajinovic, V, Vargovic, M, Lovric, D, Reskovic-Luksic, V, Vincelj, J, Jaksic Jurinjak, S, Yiannikourides, V, Ioannides, M, Pofaides, C, Masoura, V, Pudich, J, Linhart, A, Siranec, M, Marek, J, Blechova, K, Kamenik, M, Pelouch, R, Coufal, Z, Mikulica, M, Griva, M, Jancova, E, Mikulcova, M, Taborsky, M, Precek, J, Jecmenova, M, Latal, J, Widimsky, J, Butta, T, Machacek, S, Vancata, R, Spinar, J, Holicka, M, Pow Chon Long, F, Anzules, N, Bajana Carpio, A, Largacha, G, Penaherrera, E, Moreira, D, Mahfouz, E, Elsafty, E, Soliman, A, Zayed, Y, Aboulenein, J, Abdel-Hay, M, Almaghraby, A, Abdelnaby, M, Ahmed, M, Hammad, B, Saleh, Y, Zahran, H, Elgebaly, O, Saad, A, Ali, M, Zeid, A, El Sharkawy, R, Al Kholy, A, Doss, R, Osama, D, Rizk, H, Elmogy, A, Mishriky, M, Assayag, P, El Hatimi, S, Hubert, S, Casalta, J-P, Gouriet, F, Arregle, F, Cammilleri, S, Tessonnier, L, Riberi, A, Botelho-Nevers, E, Gagneux-Brunon, A, Pierrard, R, Tulane, C, Campisi, S, Fuzellier, J-F, Detoc, M, Mehalla, T, Boutoille, D, S Lecompte, A, Lefebvre, M, Pattier, S, Al Habash, O, Asseray-Madani, N, Biron, C, Brochard, J, Caillon, J, Cueff, C, Le Tourneau, T, Lecomte, R, M Magali Michel, M, Orain, J, Delarue, S, Le Bras, M, Faucher, J-F, Aboyans, V, Beeharry, A, Durox, H, Lacoste, M, Magne, J, Mohty, D, David, A, Pradel, V, Sierra, V, Neykova, A, Bettayeb, B, Elkentaoui, S, Tzvetkov, B, Landry, G, Strady, C, Ainine, K, Baumard, S, Brasselet, C, Tassigny, C, Valente-Pires, V, Lefranc, M, Hoen, B, Lefevre, B, Curlier, E, Callier, C, Fourcade, N, Jobic, Y, Ansard, S, Le Berre, R, Le Ven, F, Pouliquen, M-C, Prat, G, Le Roux, P, Bouchart, F, Savoure, A, Alarcon, C, Chapuzet, C, Gueit, I, Tribouilloy, C, Bohbot, Y, Peugnet, F, Gun, M, Duval, X, Lescure, X, Ilic-Habensus, E, Sadoul, N, Selton-Suty, C, Alla, F, Goehringer, F, Huttin, O, Chevalier, E, Garcia, R, Le Marcis, V, Tattevin, P, Flecher, E, Revest, M, Chirouze, C, Bouiller, K, Hustache-Mathieu, L, Klopfenstein, T, Moreau, J, Fournier, D, Brunel, A-S, Lim, P, Oliver, L, Ternacle, J, Moussafeur, A, Chavanet, P, Piroth, L, Salmon-Rousseau, A, Buisson, M, Mahy, S, Martins, C, Gohier, S, Axler, O, Baumann, F, Lebras, S, Piper, C, Guckel, D, Börgermann, J, Horstkotte, D, Winkelmann, E, Brockmeier, B, Grey, D, Nickenig, G, Schueler, R, Öztürk, C, Stöhr, E, Hamm, C, Walther, T, Brandt, R, Frühauf, A-C, T Hartung, C, Hellner, C, Wild, C, Becker, M, Hamada, S, Kaestner, W, Stangl, K, Knebel, F, Baldenhofer, G, Brecht, A, Dreger, H, Isner, C, Pfafflin, F, Stegemann, M, Zahn, R, Fraiture, B, Kilkowski, C, Karcher, A-K, Klinger, S, Tolksdorf, H, Tousoulis, D, Aggeli, C, Sideris, S, Venieri, E, Sarri, G, Tsiapras, D, Armenis, I, Koutsiari, A, Floros, G, Grassos, C, Dragasis, S, Rallidis, L, Varlamos, C, Michalis, L, Naka, K, Bechlioulis, A, Kotsia, A, Lakkas, L, Pappas, K, Papadopoulos, C, Kiokas, S, Lioni, A, Misailidou, S, Barbetseas, J, Bonou, M, Kapelios, C, Tomprou, I, Zerva, K, Manolis, A, Hamodraka, E, Athanasiou, D, Haralambidis, G, Samaras, H, Poulimenos, L, Nagy, A, Bartykowszki, A, Gara, E, Mungulmare, K, Kasliwal, R, Bansal, M, Ranjan, S, Bhan, A, Kyavar, M, Maleki, M, Noohi Bezanjani, F, Alizadehasl, A, Boudagh, S, Ghavidel, A, Moradnejad, P, R Pasha, H, Ghadrdoost, B, Gilon, D, Strahilevitz, J, Wanounou, M, Israel, S, D'Agostino, C, Colonna, P, De Michele, L, Fumarola, F, Stante, M, Marchionni, N, Scheggi, V, Alterini, B, Del Pace, S, Stefano, P, Sparano, C, Ruozi, N, Tenaglia, R, Muraru, D, Limbruno, U, Cresti, A, Baratta, P, Solari, M, Giannattasio, C, Moreo, A, De Chiara, B, Lopez Montero, B, Musca, F, A Orcese, C, Panzeri, F, Spano, F, F Russo, C, Alfieri, O, DE BONIS, Michele, Chiappetta, S, Del Forno, B, Ripa, M, Scarpellini, P, Tassan Din, C, Castiglioni, B, Pasciuta, R, Carletti, S, Ferrara, D, Guffanti, M, Iaci, G, Lapenna, E, Nisi, T, Oltolini, C, Busnardo, E, Pajoro, U, Agricola, E, Meneghin, R, Schiavi, D, Piscione, F, Citro, R, M Benvenga, R, Greco, L, Soriente, L, Radano, I, Prota, C, Bellino, M, Di Vece, D, Santini, F, Salsano, A, M Olivieri, G, Turrini, F, Messora, R, Tondi, S, Olaru, A, Agnoletto, V, Grassi, L, Leonardi, C, Sansoni, S, Del Ponte, S, M Actis Dato, G, De Martino, A, Ohte, N, Kikuchi, S, Wakami, K, Aonuma, K, Seo, Y, Ishizu, T, Machino-Ohtsuka, T, Yamamoto, M, Iida, N, Nakajima, H, Nakagawa, Y, Izumi, C, Amano, M, Miyake, M, Takahashi, K, Shiojima, I, Miyasaka, Y, Maeba, H, Suwa, Y, Taniguchi, N, Tsujimoto, S, Kitai, T, Ota, M, Yuda, S, Sasaki, S, Hagiwara, N, Yamazaki, K, Ashihara, K, Arai, K, Saitou, C, Saitou, S, Suzuki, G, Shibata, Y, Watanabe, N, Nishino, S, Ashikaga, K, Kuriyama, N, Mahara, K, Okubo, T, Fujimaki, H, Shitan, H, Yamamoto, H, Abe, K, Terada, M, Takanashi, S, Sata, M, Yamada, H, Kusunose, K, Saijo, Y, Seno, H, Yuichiro, O, Onishi, T, Sera, F, Nakatani, S, Mizuno, H, Sengoku, K, W Park, S, Eun Kyoung, K, Ga Yeon, L, Hwang, J-W, Jin-Oh, C, Park, S-J, Sang-Chol, L, Sung-A, C, Y Jang, S, Heo, R, Lee, S, Song, J-M, Jung, E, Plisiene, J, Dambrauskaite, A, Gruodyte, G, Jonkaitiene, R, Mizariene, V, Atkocaityte, J, Zvirblyte, R, Sow, R, Codreanu, A, Staub, T, Michaux, C, L De la Vega, E C, Jacobs-Orazi, L, Mallia Azzopardi, C, G Xuereb, R, Piscopo, T, Farrugia, J, Fenech, M, Pllaha, E, Vella, C, Borg, D, Casha, R, Grib, L, Raevschi, E, Grejdieru, A, Kravcenco, D, Prisacari, E, Samohvalov, E, Samohvalov, S, Sceglova, N, Panfile, E, Cardaniuc, L, Corcea, V, Feodorovici, A, Gaina, V, Girbu, L, Jimbei, P, Balan, G, Cardaniuc, I, Benesco, I, Marian, V, Sumarga, N, Bozovic, B, Bulatovic, N, Lakovic, P, Music, L, Budde, R, Wahadat, A, Gamela, T, Meijers, T, P Van Melle, J, M Deursen, V, J Crijns, H, C Bekkers, S, C Cheriex, E, Gilbers, M, L Kietselaer, B, Knackstedt, C, Lorusso, R, Schalla, S, A Streukens, S, Chamuleau, S, Cramer, M-J, Teske, A, Van der Spoel, T, Wind, A, Lokhorst, J, Liesbek, O, Van Heusden, H, Tanis, W, Van der Bilt, I, Vriend, J, De Lange-van Bruggen, H, Karijodikoro, E, Riezebos, R, van Dongen, E, Schoep, J, Stolk, V, T Offstad, J, O Beitnes, J, Helle-Valle, T, Skulstad, H, Skardal, R, Qamar, N, Furnaz, S, Ahmed, B, H Butt, M, F Khanzada, M, Saghir, T, Wahid, A, Hryniewiecki, T, Szymanski, P, Marzec, K, Misztal-Ogonowska, M, Kosmala, W, Przewlocka-Kosmala, M, Rojek, A, Woznicka, K, Zachwyc, J, Lisowska, A, Kaminska, M, D Kasprzak, J, Kowalczyk, E, F Strzecka, D, Wejner-Mik, P, Trabulo, M, Freitas, P, Ranchordas, S, Rodrigues, G, Pinto, P, Queiros, C, Azevedo, J, Marques, L, Seabra, D, Branco, L, Cruz, M, Galrinho, A, Moreira, R, Rio, P, T Timoteo, A, Selas, M, Carmelo, V, Duque Neves, B, Pereira, H, Guerra, A, Marques, A, Pintassilgo, I, C Tomescu, M, Trofenciuc, N-M, Andor, M, Bordejevic, A, S Branea, H, Caruntu, F, A Velcean, L, Mavrea, A, F Onel, M, Parvanescu, T, Pop, D, L Pop-Moldovan, A, I Puticiu, M, Cirin, L, M Citu, I, A Cotoraci, C, Darabantiu, D, Farcas, R, Marincu, I, Ionac, A, Cozma, D, Mornos, C, Goanta, F, Popescu, I, Beyer, R, Mada, R, Rancea, R, Tomoaia, R, Rosianu, H, Stanescu, C, Kobalava, Z, Karaulova, J, Kotova, E, Milto, A, Pisaryuk, A, Povalyaev, N, Sorokina, M, Alrahimi, J, Elshiekh, A, Jamiel, A, Ahmed, A, Attia, N, Putnikovic, B, Dimic, A, Ivanovic, B, Matic, S, Trifunovic, D, Petrovic, J, Kosevic, D, Stojanovic, I, Petrovic, I, Dabic, P, Milojevic, P, Srdanovic, I, Susak, S, Velicki, L, Vulin, A, Kovacevic, M, Redzek, A, Stefanovic, M, C Yeo, T, Kf Kong, W, K Poh, K, Vilacosta, I, Ferrera, C, Olmos, C, Abd El-Nasser, M, Calvo Iglesias, F, Blanco-Gonzalez, E, Bravo Amaro, M, Lopez-Rodriguez, E, Lugo Adan, J, N Germinas, A, Pazos-Lopez, P, Pereira Loureiro, M, T Perez, M, Raposeiras-Roubin, S, Rasheed Yas, S, Suarez-Varela, M-M, Vasallo Vidal, F, Garcia-Dorado, D, Fernandez-Hidalgo, N, Gonzalez-Alujas, T, Lozano, J, Maisterra, O, Pizzi, N, Rios, R, Bayes-Genis, A, Pedro Botet, L, Vallejo, N, Llibre, C, Mateu, L, Nunez, R, Quesada, D, Berastegui, E, Bosch Portell, D, Aboal Vinas, J, Albert Bertran, X, Brugada Tarradellas, R, Loma-Osorio Ricon, P, Tiron de Llano, C, A Arnau, M, Bel, A, Blanes, M, Osa, A, Anguita, M, Carrasco, F, C Castillo, J, L Zamorano, J, L Moya Mur, J, Alvaro, M, Fernandez-Golfin, C, M Monteagudo, J, Navas Elorza, E, C Farinas Alvarez, M, Aguero Balbin, J, Zarauza, J, F Gutierrez-Diez, J, Arminanzas, C, Arnaiz de Las Revillas, F, Arnaiz Garcia, A, Cobo Belaustegui, M, Fernandez Sampedro, M, Gutierrez Cuadra, M, Garcia Cuello, L, Gonzalez Rico, C, Rodriguez-Alvarez, R, Goikoetxea, J, Montejo, M, M Miro, J, Almela, M, Ambrosioni, J, Moreno, A, Quintana, E, Sandoval, E, Tellez, A, M Tolosana, J, Vidal, B, Falces, C, Fuster, D, Garcia-de-la-Maria, C, Hernandez-Meneses, M, Llopis, J, Marco, F, Ruiz-Zamora, I, Bardaji Ruiz, A, Sanz Girgas, E, Garcia-Pardo, G, Guillen Marzo, M, Rodriguez Oviedo, A, Villares Jimenez, A, Abid, L, Hammami, R, Kammoun, S, S Mourali, M, Mghaieth Zghal, F, Ben Hlima, M, Boudiche, S, Ouali, S, Zakhama, L, Antit, S, Slama, I, Gulel, O, Sahin, M, Karacaglar, E, Kucukoglu, S, Cetinarslan, O, Y Sinan, U, Canpolat, U, Mutlu, B, Atas, H, Dervishova, R, Ileri, C, Alhashmi, J, Tahir, J, Zarger, P, Baslib, F, Woldman, S, Menezes, L, Primus, C, Uppal, R, Bvekerwa, I, Chandrasekaran, B, Kopanska, A, Chambers, J, Hancock, J, Klein, J, Rajani, R, P Ursi, M, Cannata, S, Dworakowski, R, Fife, A, Breeze, J, Browne-Morgan, M, Gunning, M, Streather, S, M Asch, F, Zemedkun, M, Alyavi, B, Uzokov, J, Hôpital de la Timone [CHU - APHM] (TIMONE), Microbes évolution phylogénie et infections (MEPHI), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), University Medical Center Groningen [Groningen] (UMCG), Laboratoire Traitement du Signal et de l'Image (LTSI), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Pontchaillou [Rennes], Université de Médecine Carol Davila, Guy's and St Thomas' Hospital [London], CHU Henri Mondor, Centre Hospitalier Universitaire de Liège (CHU-Liège), AstraZeneca, Bayer, Edwards Lifesciences, Servier, Abbott Vascular Int., Amgen Cardiovascular, Pfizer Alliance, Daiichi Sankyo Europe GmbH, Alliance Daiichi Sankyo Europe GmbH, Gedeon Richter Plc., Menarini Int. Op., Vifor, Boehringer Ingelheim, Boston Scientific Corporation, Bristol-Myers Squibb, Eli Lilly and Company, UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, UCL - (SLuc) Service de pathologie cardiovasculaire, UCL - (SLuc) Service de pathologies cardiovasculaires intensives, UCL - (SLuc) Service de soins intensifs, Service de cardiologie, Université de la Méditerranée - Aix-Marseille 2-Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU), CIC - CHU Bichat, Institut National de la Santé et de la Recherche Médicale (INSERM), Service de cardiologie et maladies vasculaires, Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-CHU Pontchaillou [Rennes], Oxford University Hospitals NHS Trust, University of Oxford [Oxford], Université Paris-Est Créteil Val-de-Marne - Faculté de médecine (UPEC Médecine), Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Université de Bordeaux (UB), Research Center [Associazione Nazionale Medici Cardiologi Ospedalieri] (ANMCO Research Center), Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO), Service de cardiologie [Liège], CHU de Liège-Domaine Universitaire du Sart Tilman, Paris-Centre de Recherche Cardiovasculaire (PARCC - UMR-S U970), Université Paris Descartes - Paris 5 (UPD5)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Institut National de la Santé et de la Recherche Médicale (INSERM), University of Exeter, Instituto Nacional de Tecnología Agropecuaria, Pergamino, Argentina, Laboratory of In Vivo Cellular and Molecular Imaging, Vrije Universiteit Brussel (VUB), Centre National de la Recherche Scientifique (CNRS), Division of Engineering and Applied Science, California Institute of Technology, California Institute of Technology (CALTECH), Departamento de Biologia de la Reproduccion, Universidad Autónoma Metropolitana Iztapalapa (UAMI), Universidade Federal de Itajubá, Departamento de Física [Coimbra] (DFC), Universidade de Coimbra [Coimbra], Section of Internal Medicine and Endocrine and Metabolic Sciences, Università degli Studi di Perugia (UNIPG), LIP-Coimbra & Department of Physics of the University of Coimbra, Service Hospitalier Frédéric Joliot (SHFJ), Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay, Quebec Heart Institute/Laval Hospital, Université Laval [Québec] (ULaval)-Quebec Heart Institute, Institut Lavoisier de Versailles (ILV), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Centre National de la Recherche Scientifique (CNRS), Institut Hospitalier Universitaire Méditerranée Infection (IHU AMU), CHU Saint-Etienne, Centre Hospitalier Universitaire de Saint-Etienne (CHU de Saint-Etienne), Service des maladies infectieuses et tropicales [CHU Nantes], Centre hospitalier universitaire de Nantes (CHU Nantes), Service de bactériologie et hygiène hospitalière [Nantes], Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes), Institut du thorax, Université de Nantes (UN)-IFR26-Institut National de la Santé et de la Recherche Médicale (INSERM), Service des Maladies infectieuses et tropicales [CHU Limoges], CHU Limoges, Hôpital Sainte-Marguerite [CHU - APHM] (Hôpitaux Sud ), Centre Hospitalier Universitaire de Reims (CHU Reims), Anesthésie et réanimation en chirurgie cardiaque [CHU Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU), Normandie Université (NU), Service des maladies infectieuses et tropicales [Rouen], Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Mécanismes physiologiques et conséquences des calcifications cardiovasculaires: rôle des remodelages cardiovasculaires et osseux, Université de Picardie Jules Verne (UPJV)-Institut National de la Santé et de la Recherche Médicale (INSERM), Department of Cardiology [Ospedali del Tigullio], Modèles et méthodes de l'évaluation thérapeutique des maladies chroniques (U738 / UMR_S738), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Diderot - Paris 7 (UPD7), Institut Lorrain du Coeur et des Vaisseaux Louis Mathieu [Nancy], Maladies chroniques, santé perçue, et processus d'adaptation (APEMAC), Université de Lorraine (UL), Service des Maladies Infectieuses et Tropicales [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Service de Cardiologie [CHRU Nancy], Service des maladies infectieuses et réanimation médicale, Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou, Service de chirurgie thoracique cardiaque et vasculaire [Rennes], Laboratoire Chrono-environnement - CNRS - UFC (UMR 6249) (LCE), Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), service de maladies infectieuses CHU J Minjoz Besancon, Hôpital Jean Minjoz, Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon), Département d'infectiologie (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Virologie et pathogenèse virale (VPV), Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon, Institució Catalana de Recerca i Estudis Avançats (ICREA), Institute for Advanced Studies in Basic Sciences, affiliation inconnue, Dipartamento di Fisica 'E.R. Caianiello', Università degli Studi di Salerno (UNISA), The University of Tokyo, Northern Research Station, Forestry Commission, University of North Carolina [Chapel Hill] (UNC), University of North Carolina System (UNC), Instituto de Plasmas e Fusão Nuclear [Lisboa] (IPFN), Instituto Superior Técnico, Universidade Técnica de Lisboa (IST), Instituto de Investigaciones Marinas (CSIC), Faculté des Sciences Pharmaceutiques, EA 4529, Laboratoire de Biochimie, Université Paris-Sud - Paris 11 (UP11), Istituto di Virologia Vegetale, Università degli studi di Torino (UNITO), Universidad Nacional Autónoma de México (UNAM), Service de Chirurgie Cardiovasculaire, University Hospital of Cruces, Geneva University Hospital (HUG), Institut Jean Le Rond d'Alembert (DALEMBERT), Université Pierre et Marie Curie - Paris 6 (UPMC)-Centre National de la Recherche Scientifique (CNRS), Preventive Medicine Unit, University Hospital Joan XXIII, IISPV, Rovira and Virgili University, Popescu, B, Maggioni, A, Gale, C, Nagy, V, Petronio, A, Ali Tatar-Chentir, N, Badano, L, Cardim, N, Chan, K, Kang, D, Neskovic, A, Sade, L, Tude Rodrigues, A, Plastino, M, Casabe, J, Stollberger, C, Ho, C, Winter, M, Emal, C, Vanoverschelde, J, Andrade, J, Miglioranza, M, Shuha, D, Siciliano, A, Falcao, S, Moises, V, Mancuso, F, Souza, A, Silva, C, Joao, G, Abboud, C, Assef, J, Della Togna, D, Romero Oliveira, A, Gelape, C, Peirira Nunes, M, De Abreu Ferrari, T, Sebag, I, Rudski, L, Casalta, J, Fuzellier, J, Lecompte, A, Magali Michel, M, Faucher, J, Pouliquen, M, Brunel, A, Borgermann, J, Ozturk, C, Stohr, E, Fruhauf, A, Hartung, C, Karcher, A, Pasha, H, Orcese, C, Russo, C, De Bonis, M, Benvenga, R, Olivieri, G, Actis Dato, G, Park, S, Hwang, J, Jang, S, Song, J, De la Vega, E, Xuereb, R, Van Melle, J, Deursen, V, Crijns, H, Bekkers, S, Cheriex, E, Kietselaer, B, Streukens, S, Cramer, M, Offstad, J, Beitnes, J, Butt, M, Khanzada, M, Kasprzak, J, Strzecka, D, Timoteo, A, Tomescu, M, Trofenciuc, N, Branea, H, Velcean, L, Onel, M, Pop-Moldovan, A, Puticiu, M, Citu, I, Cotoraci, C, Yeo, T, Poh, K, Germinas, A, Perez, M, Suarez-Varela, M, Arnau, M, Castillo, J, Zamorano, J, Moya Mur, J, Monteagudo, J, Farinas Alvarez, M, Gutierrez-Diez, J, Miro, J, Tolosana, J, Mourali, M, Yasar, U, Ursi, M, Asch, F, Clinical sciences, Cardio-vascular diseases, Cardiology, Medical Imaging, Cardiovascular Centre (CVC), Service de médecine nucléaire [Marseille], Imagerie MOléculaire pour applications THéranostiques personnalisées (IMOTHEP), Institut FRESNEL (FRESNEL), Aix Marseille Université (AMU)-École Centrale de Marseille (ECM)-Centre National de la Recherche Scientifique (CNRS)-Aix Marseille Université (AMU)-École Centrale de Marseille (ECM)-Centre National de la Recherche Scientifique (CNRS)- Hôpital de la Timone [CHU - APHM] (TIMONE), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris-Saclay-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Centre National de la Recherche Scientifique (CNRS)-Université Pierre et Marie Curie - Paris 6 (UPMC), MGSOG Scientific staff, MUMC+: MA Cardiologie (9), Cardiologie, RS: Carim - H01 Clinical atrial fibrillation, RS: CARIM - R2.01 - Clinical atrial fibrillation, RS: CARIM - R3.11 - Imaging, Promovendi CD, Fysiologie, MUMC+: MA Med Staf Artsass CTC (9), RS: CARIM - R1.06 - Genetic Epidemiology and Genomics of cardiovascular diseases, MUMC+: MA Med Staf Spec Cardiologie (9), RS: Carim - H02 Cardiomyopathy, RS: CARIM - R2.02 - Cardiomyopathy, CTC, MUMC+: MA Med Staf Spec CTC (9), RS: Carim - V04 Surgical intervention, RS: CARIM - R2.12 - Surgical intervention, RS: FdR IC Aansprakelijkheid, Graduate School, ACS - Heart failure & arrhythmias, Radiotherapy, CCA - Imaging and biomarkers, CCA - Cancer Treatment and Quality of Life, and ACS - Atherosclerosis & ischemic syndromes
- Subjects
Male ,SURGERY ,Embolism ,Infective endocarditi ,Infective endocarditis ,Registry ,Valve disease ,030204 cardiovascular system & hematology ,0302 clinical medicine ,Africa, Northern ,Positron Emission Tomography Computed Tomography ,030212 general & internal medicine ,Hospital Mortality ,Prospective Studies ,Registries ,Prospective cohort study ,Abscess ,Aged, 80 and over ,medicine.diagnostic_test ,Middle Aged ,Staphylococcal Infections ,3. Good health ,Cardiac surgery ,Community-Acquired Infections ,Europe ,Treatment Outcome ,Positron emission tomography ,Echocardiography ,Heart Valve Prosthesis ,[SDV.IB]Life Sciences [q-bio]/Bioengineering ,Female ,ECHOCARDIOGRAPHY ,Cardiology and Cardiovascular Medicine ,Adult ,medicine.medical_specialty ,Asia ,Prosthesis-Related Infections ,DIAGNOSIS ,03 medical and health sciences ,Fluorodeoxyglucose F18 ,Internal medicine ,Streptococcal Infections ,medicine ,MANAGEMENT ,Journal Article ,Humans ,Aged ,business.industry ,EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY ,Endocarditis, Bacterial ,South America ,medicine.disease ,Heart failure ,Etiology ,Radiopharmaceuticals ,business ,[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology ,Enterococcus - Abstract
Aims The EURO-ENDO registry aimed to study the management and outcomes of patients with infective endocarditis (IE). Methods and results Prospective cohort of 3116 adult patients (2470 from Europe, 646 from non-ESC countries), admitted to 156 hospitals in 40 countries between January 2016 and March 2018 with a diagnosis of IE based on ESC 2015 diagnostic criteria. Clinical, biological, microbiological, and imaging [echocardiography, computed tomography (CT) scan, 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT)] data were collected. Infective endocarditis was native (NVE) in 1764 (56.6%) patients, prosthetic (PVIE) in 939 (30.1%), and device-related (CDRIE) in 308 (9.9%). Infective endocarditis was community-acquired in 2046 (65.66%) patients. Microorganisms involved were staphylococci in 1085 (44.1%) patients, oral streptococci in 304 (12.3%), enterococci in 390 (15.8%), and Streptococcus gallolyticus in 162 (6.6%). 18F-fluorodeoxyglucose positron emission tomography/computed tomography was performed in 518 (16.6%) patients and presented with cardiac uptake (major criterion) in 222 (42.9%) patients, with a better sensitivity in PVIE (66.8%) than in NVE (28.0%) and CDRIE (16.3%). Embolic events occurred in 20.6% of patients, and were significantly associated with tricuspid or pulmonary IE, presence of a vegetation and Staphylococcus aureus IE. According to ESC guidelines, cardiac surgery was indicated in 2160 (69.3%) patients, but finally performed in only 1596 (73.9%) of them. In-hospital death occurred in 532 (17.1%) patients and was more frequent in PVIE. Independent predictors of mortality were Charlson index, creatinine > 2 mg/dL, congestive heart failure, vegetation length > 10 mm, cerebral complications, abscess, and failure to undertake surgery when indicated. Conclusion Infective endocarditis is still a life-threatening disease with frequent lethal outcome despite profound changes in its clinical, microbiological, imaging, and therapeutic profiles.
- Published
- 2019
- Full Text
- View/download PDF
13. Computed tomographic retrograde positive contrast cystography and computed tomographic excretory urography characterization of a urinary bladder diverticulum in a dog
- Author
-
Gustavo A. Ramírez, Ramón M. Almela, Esteban Iglesias, Agustina Anson, Jose M. Larrinaga, Vicente Cervera, and Carina Strohmayer
- Subjects
Male ,medicine.medical_specialty ,Cystography ,Exploratory laparotomy ,medicine.medical_treatment ,Radiography ,Urinary Bladder ,Diagnosis, Differential ,03 medical and health sciences ,Dogs ,0302 clinical medicine ,Dysuria ,medicine ,Animals ,Dog Diseases ,Compartment (pharmacokinetics) ,Urinary bladder ,General Veterinary ,medicine.diagnostic_test ,business.industry ,Urography ,Anatomy ,medicine.disease ,Diverticulum ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,030211 gastroenterology & hepatology ,Histopathology ,medicine.symptom ,Tomography, X-Ray Computed ,business - Abstract
A one-year-old intact male German shepherd dog was referred with a 3-month history of dysuria and pollakiuria. Physical examination revealed a large firm mass in the caudal abdomen. Findings from survey radiography, negative contrast cystography, computed tomographic (CT) retrograde positive contrast cystography, and CT excretory urography were consistent with a large urinary bladder diverticulum. An exploratory laparotomy revealed a normal wall appearance in the ventral compartment (true bladder) and marked thinning of the wall in the dorsal compartment (diverticulum). Both ureters inserted into the ventral compartment. The dorsal compartment was excised and histopathology confirmed the diagnosis of urinary bladder diverticulum.
- Published
- 2018
- Full Text
- View/download PDF
14. Selected serum oxidative stress biomarkers in dogs with non-food-induced and food-induced atopic dermatitis
- Author
-
Ramón M. Almela, Camila Peres Rubio, José J. Cerón, Alexander Tichy, Agustina Ansón, and Ursula Mayer
- Subjects
0301 basic medicine ,medicine.medical_specialty ,040301 veterinary sciences ,Trolox equivalent antioxidant capacity ,medicine.disease_cause ,Gastroenterology ,Dermatitis, Atopic ,0403 veterinary science ,Pathogenesis ,Cohort Studies ,03 medical and health sciences ,Dogs ,Serum biomarkers ,Internal medicine ,medicine ,Animals ,Clinical significance ,Dog Diseases ,General Veterinary ,business.industry ,04 agricultural and veterinary sciences ,Atopic dermatitis ,medicine.disease ,PON1 ,Oxidative Stress ,030104 developmental biology ,business ,Oxidative stress ,Biomarkers ,Food Hypersensitivity ,Cohort study - Abstract
Background Oxidative stress (OS) has been shown to be involved in the pathogenesis of human and canine atopic dermatitis (AD) through several distinct mechanisms. Selected serum biomarkers of OS (sbOS) have been validated in normal dogs and studied in several canine diseases. To the best of the authors' knowledge, the sbOS evaluated in this study have not previously been described in canine AD. Hypothesis/objectives The aims of the study were to evaluate a panel of sbOS in dogs with food-induced (FIAD) and non-food-induced (NFIAD) AD: cupric reducing antioxidant capacity (CUPRAC), ferrous oxidation-xylenol orange (FOX), ferric reducing ability of the plasma (FRAP), paraoxonase-1 (PON1), trolox equivalent antioxidant capacity (TEAC) and serum total thiol (THIOL). The aim was to compare these metabolites with those in healthy control dogs, and to correlate sbOS with validated pruritus and CADESI-04 severity scales in dogs with AD. Animals Forty six healthy, nine NFIAD and three FIAD client-owned dogs were included. Methods The study was designed as a cohort study. Results There were significant differences in atopic dogs when compared to healthy dogs for all of the sbOS analysed. Conclusions and clinical relevance These findings suggest that OS could play a role in the pathogenesis of canine NFIAD and FIAD. In addition, the evaluation of sbOS could be useful for precision medicine to help to detect atopic dogs that might benefit from antioxidant-targeted therapies.
- Published
- 2017
15. Changes in the treatment of Enterococcus faecalis infective endocarditis in Spain in the last 15 years: from ampicillin plus gentamicin to ampicillin plus ceftriaxone
- Author
-
J.M. Pericas, C. Cervera, A. del Rio, A. Moreno, C. Garcia de la Maria, M. Almela, C. Falces, S. Ninot, X. Castañeda, Y. Armero, D. Soy, J.M. Gatell, F. Marco, C.A. Mestres, J.M. Miro, and null The Hospital Clinic Endocarditis Study Group
- Subjects
Male ,Microbiology (medical) ,Ampicillin plus ceftriaxone ,outcomes ,Enterococcus faecalis ,Microbiology ,Cohort Studies ,Antibiotic resistance ,Ampicillin ,Drug Resistance, Bacterial ,medicine ,Humans ,Prospective Studies ,Renal Insufficiency ,antimicrobial treatment ,Prospective cohort study ,Gram-Positive Bacterial Infections ,Aged ,Aged, 80 and over ,Endocarditis ,biology ,infective endocarditis ,business.industry ,Ceftriaxone ,General Medicine ,Middle Aged ,medicine.disease ,biology.organism_classification ,Survival Analysis ,Anti-Bacterial Agents ,Treatment Outcome ,Infectious Diseases ,Withholding Treatment ,Spain ,Streptomycin ,Infective endocarditis ,Drug Therapy, Combination ,Female ,Gentamicin ,high-level aminoglycoside resistance ,Gentamicins ,business ,medicine.drug - Abstract
The aim of this study was to assess changes in antibiotic resistance, epidemiology and outcome among patients with Enterococcus faecalis infective endocarditis (EFIE) and to compare the efficacy and safety of the combination of ampicillin and gentamicin (A+G) with that of ampicillin plus ceftriaxone (A+C). The study was a retrospective analysis of a prospective cohort of EFIE patients treated in our centre from 1997 to 2011. Thirty patients were initially treated with A+G (ampicillin 2 g/4 h and gentamicin 3 mg/kg/day) and 39 with A+C (ampicillin 2 g/4 h and ceftriaxone 2 g/12 h) for 4–6 weeks. Increased rates of high-level aminoglycoside resistance (HLAR; gentamicin MIC ≥512 mg/L, streptomycin MIC ≥1024 mg/L or both) were observed in recent years (24% in 1997–2006 and 49% in 2007–2011; p 0.03). The use of A+C increased over time: 1997–2001, 4/18 (22%); 2002–2006, 5/16 (31%); 2007–2011, 30/35 (86%) (p
- Published
- 2014
- Full Text
- View/download PDF
16. Fall 26: 5-jähriger Europäisch-Kurzhaar-Kater mit kutaner krustöser Dermatitis
- Author
-
Ramón M. Almela
- Subjects
0403 veterinary science ,030207 dermatology & venereal diseases ,03 medical and health sciences ,0302 clinical medicine ,040301 veterinary sciences ,business.industry ,Medicine ,04 agricultural and veterinary sciences ,business - Published
- 2018
- Full Text
- View/download PDF
17. Should precision medicine be encouraged in veterinary dermatology?
- Author
-
Ramón M. Almela and Wolfgang Bäumer
- Subjects
Veterinary Medicine ,medicine.medical_specialty ,General Veterinary ,040301 veterinary sciences ,business.industry ,04 agricultural and veterinary sciences ,Dermatology ,Precision medicine ,0403 veterinary science ,03 medical and health sciences ,0302 clinical medicine ,Medicine ,Veterinary dermatology ,Animals ,Medical physics ,030212 general & internal medicine ,Precision Medicine ,business - Published
- 2017
18. Impact of fluconazole susceptibility on the outcome of patients with candidaemia: data from a population-based surveillance
- Author
-
M. Fernández-Ruiz, J. Guinea, D. Lora-Pablos, Ó. Zaragoza, M. Puig-Asensio, B. Almirante, M. Cuenca-Estrella, J.M. Aguado, B. Padilla, P. Muñoz, J.R. Paño Pardo, J. García-Rodríguez, C.G. Cerrada, J. Fortún, P. Martín, E. Gómez, P. Ryan, C. Campelo, I. de los Santos Gil, V. Buendía, B.P. Gorricho, M. Alonso, F.S. Sanz, P. Merino, F. González Romo, M. Gorgolas, I. Gadea, J.E. Losa, A. Delgado-Iribarren, A. Ramos, Y. Romero, I.S. Romero, O. Zaragoza, J. Rodríguez-Baño, A.I. Suarez, A. Loza, A.I. Aller García, E. Martín-Mazuelos, M.R. Pérez de Pipaón, J. Garnacho, C. Ortiz, M. Chávez, F.L. Maroto, M. Salavert, J. Pemán, J. Blanquer, D. Navarro, J.J. Camarena, R. Zaragoza, V. Abril, C. Gimeno, S. Hernández, G. Ezpeleta, E. Bereciartua, J.L. Hernández Almaraz, M. Montejo, R.A. Rivas, R. Ayarza, A.M. Planes, I.R. Camps, J. Mensa, M. Almela, M. Gurgui, F. Sánchez-Reus, J. Martínez-Montauti, M. Sierra, J.P. Horcajada, L. Sorli, J. Gómez, A. Gené, M. Urrea, A. Mularoni, M. Valerio, A. Díaz-Martín, F. Puchades, Gilead Sciences, MSD, Astellas Pharma, Pfizer, Fundación SEIMC-GESIDA, Ministerio de Economía y Competitividad (España), Instituto de Salud Carlos III, European Commission, Red Española de Investigación en Patología Infecciosa, Fundación Mutua Madrileña, MicoLab, Merck Sharp & Dohme de España, Hikma Pharmaceuticals, United Medical Corporation, Novartis, bioMérieux, Schering-Plough, Fundación Francisco Soria Melguizo, Ferrer International, Ministerio de Asuntos Exteriores y Cooperación (España), Ministerio de Educación y Cultura (España), Ministerio de Sanidad, Servicios Sociales e Igualdad (España), Fundación Ramón Areces, [Fernandez-Ruiz, M.] Univ Complutense, Inst Invest Hosp Octubre i 12 12, Hosp Univ Octubre 12, Unit Infect Dis, Madrid, Spain, [Aguado, J. M.] Univ Complutense, Inst Invest Hosp Octubre i 12 12, Hosp Univ Octubre 12, Unit Infect Dis, Madrid, Spain, [Guinea, J.] Univ Complutense, Hosp Gen Univ Gregorio Maranon, Dept Clin Microbiol & Infect Dis, Madrid, Spain, [Lora-Pablos, D.] Hosp Univ Octubre 12, Inst Invest Hosp Octubre i 12 12, Unit Clin Res, Madrid, Spain, [Lora-Pablos, D.] CIBER Epidemiol & Salud Publ CIBERESP, Madrid, Spain, [Zaragoza, O.] Inst Salud Carlos III, Spanish Natl Ctr Microbiol, Dept Mycol, Madrid, Spain, [Cuenca-Estrella, M.] Inst Salud Carlos III, Spanish Natl Ctr Microbiol, Dept Mycol, Madrid, Spain, [Puig-Asensio, M.] Univ Autonoma Barcelona, Dept Med, Hosp Univ Vall dHebron, Dept Infect Dis, Barcelona, Spain, [Almirante, B.] Univ Autonoma Barcelona, Dept Med, Hosp Univ Vall dHebron, Dept Infect Dis, Barcelona, Spain, Gilead, Astellas, Fundacion SEIMC-GESIDA, Spanish Ministry of Economy and Competitiveness, Instituto de Salud Carlos III - European Development Regional Fund (ERDF) 'A Way to Achieve Europe'), Spanish Network for the Research in Infectious Diseases, Spanish Ministry of Economy and Competitiveness, Instituto de Salud Carlos III, MICOLAB, Mutua Madrilena Foundation, Spanish Health Research Fund (FIS), Merck Sharp Dohme, Hickma Pharmaceutica, United Medical, bioMerieux, Schering Plough, Soria Melguizo SA, Europea Union, ALBAN program, Spanish Agency for International Cooperation, Spanish Ministry of Culture and Education, Spanish Health Research Fund, Instituto de Salud Carlos III (Spanish Ministry of Economy and Competitiveness), Ramon Areces Foundation, and Mutua Madrileria Foundation
- Subjects
0301 basic medicine ,Male ,Antifungal Agents ,Nonneutropenic patients ,Dose/mic ratio ,0302 clinical medicine ,030212 general & internal medicine ,Blood-stream infection ,Fluconazole ,Outcome ,Candida ,Aged, 80 and over ,education.field_of_study ,Diseases society ,General Medicine ,Middle Aged ,PK/PD parameters ,Infectious Diseases ,Treatment Outcome ,Propensity score analysis ,Female ,medicine.drug ,Microbiology (medical) ,medicine.medical_specialty ,Therapeutic response ,030106 microbiology ,Population ,Population based ,Microbial Sensitivity Tests ,03 medical and health sciences ,Minimum inhibitory concentration ,Candidaemia ,Pharmacokinetics ,Drug Resistance, Fungal ,Internal medicine ,Interpretive breakpoints ,medicine ,Humans ,education ,Aged ,business.industry ,Candidemia ,Odds ratio ,Confidence interval ,Surgery ,Cross-Sectional Studies ,Susceptibility ,Pharmacodynamics ,Critically-ill patients ,business ,Antifungal susceptibility - Abstract
CANDIPOP Project: B. Padilla, P. Muñoz, J. Guinea, J. R. Paño Pardo, J. García-Rodríguez, C. G. Cerrada, J. Fortún, P. Martín, E. Gómez, P. Ryan, C. Campelo, I. de los Santos, Gil, V. Buendía, B. P. Gorricho, M. Alonso, F. S. Sanz, J. M. Aguado, P. Merino, F. González Romo, M. Gorgolas, I. Gadea, J. E. Losa, A. Delgado-Iribarren, A. Ramos, Y. Romero, I. S. Romero, O. Zaragoza, M. Cuenca-Estrella, J. Rodríguez-Baño, A. I. Suarez, A. Loza, A. I. Aller García, E. Martín-Mazuelos, M. R. Pérez de Pipaón, J. Garnacho, C. Ortiz, M. Chávez, F. L. Maroto, M. Salavert, J. Pemán, J. Blanquer, D. Navarro, J. J. Camarena, R. Zaragoza, V. Abril, C. Gimeno, S. Hernández, G. Ezpeleta, E. Bereciartua, J. L. Hernández Almaraz, M. Montejo, R. A. Rivas, R. Ayarza, A. M. Planes, I. R. Camps, B. Almirante, J. Mensa, M. Almela, M. Gurgui, F. Sánchez-Reus, J. Martínez-Montauti, M. Sierra, J. P. Horcajada, L.Sorli, J. Gómez, A. Gené, M. Urrea, A. Mularoni, M.Valerio, A. Díaz-Martín, F. Puchades., [Objectives] The clinical correlation of fluconazole antifungal susceptibility testing (AST) for Candida isolates and its integration with pharmacokinetics/pharmacodynamics (PK/PD) parameters is unclear. We analysed the impact of fluconazole minimum inhibitory concentration (MIC) values, 24-hour area under the concentration–time curve (AUC24) and AUC24/MIC ratio on the outcome of candidemic patients., [Methods] We included 257 episodes of candidaemia treated with fluconazole monotherapy for ≥72 hours from a population-based surveillance conducted in 29 hospitals (CANDIPOP Project). AST was centrally performed by European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Clinical and Laboratory Standards Institute (CLSI) microdilution methods. Primary outcome was clinical failure (30-day mortality and/or persistent candidaemia for ≥72 hours from initiation of therapy). Secondary outcomes included early (3–7 days) and late (3–30 days) mortality., [Results] Rates of clinical failure, early and late mortality among evaluable episodes were 32.3% (80/248), 3.1% (8/257) and 23.4% (59/248). There was no relationship between fluconazole MIC values or PK/PD parameters and clinical failure. Although MIC values ≥2 mg/L by EUCAST (positive predictive value 32.1%, negative predictive value 68.7%) and ≥0.5 mg/L by CLSI (positive predictive value 34.8%, negative predictive value 74.4%) appeared to be optimal for predicting clinical failure, no significant associations remained after multivariate adjustment (odds ratio 1.67; 95% confidence interval 0.48–5.79; p 0.423). Lack of association was consistent for alternative thresholds (including proposed clinical breakpoints). The only association found for secondary outcomes was between an AUC24/MIC ratio >400 h by CLSI and early mortality (odds ratio 0.18; 95% confidence interval 0.04–0.98; p 0.026)., [Conclusions] High fluconazole MIC values did not negatively impact outcome of patients with candidaemia treated with fluconazole. No effect of PK/PD targets on the risk of clinical failure was found., Supported in part by nonrestrictive research grants from Gilead, MSD, Astellas and Pfizer. This study was cofunded by Fundación SEIMC-GESIDA; the Spanish Ministry of Economy and Competitiveness, Instituto de Salud Carlos III (cofinanced by the European Development Regional Fund (ERDF) ‘A Way to Achieve Europe’); and the Spanish Network for the Research in Infectious Diseases (REIPI RD12/0015). MFR holds a ‘Juan Rodés’ clinical research contract (JR14/00036) and JG a ‘Miguel Servet’ contract (CPII15/00006), both from the Spanish Ministry of Economy and Competitiveness, Instituto de Salud Carlos III. MFR has received honoraria for talks on behalf of Pfizer and Gilead Sciences. JG has received grant support from Astellas Pharma, MICOLAB, the Mutua Madrileña Foundation and the Spanish Health Research Fund (FIS). He has been paid for talks on behalf of Gilead Sciences, Merck Sharp & Dohme, Pfizer, Astellas Pharma, Hickma Pharmaceutica and United Medical. BA has received grant support from Gilead Sciences, Pfizer and the Instituto de Salud Carlos III. He has received honoraria for talks on behalf of Gilead Sciences, Merck Sharp & Dohme, Pfizer, Astellas Pharma and Novartis. BP has received honoraria for talks on behalf of Gilead Sciences, Merck Sharp & Dohme, Pfizer, Astellas Pharma and Novartis. MCE has received grant support from Astellas Pharma, bioMérieux, Gilead Sciences, Merck Sharp & Dohme, Pfizer, Schering Plough, Soria Melguizo SA, Ferrer International, the Europea Union, the ALBAN program, the Spanish Agency for International Cooperation, the Spanish Ministry of Culture and Education, the Spanish Health Research Fund, the Instituto de Salud Carlos III (Spanish Ministry of Economy and Competitiveness), the Ramon Areces Foundation and the Mutua Madrileña Foundation.
- Published
- 2017
19. Geographical variation in therapy for bloodstream infections due to multidrug-resistant Enterobacteriaceae: a post-hoc analysis of the INCREMENT study
- Author
-
Harris, P.N.A. Pezzani, M.D. Gutiérrez-Gutiérrez, B. Viale, P. Hsueh, P.-R. Ruiz-Garbajosa, P. Venditti, M. Tumbarello, M. Navarro-Francisco, C. Calbo, E. Akova, M. Giamarellou, H. Oliver, A. Almirante, B. Gasch, O. Martínez-Martínez, L. Schwaber, M.J. Daikos, G. Pitout, J. Peña, C. Hernández-Torres, A. Doi, Y. Pérez, F. Tuon, F.F. Tacconelli, E. Carmeli, Y. Bonomo, R.A. Pascual, Á. Paterson, D.L. Rodríguez-Baño, J. del Toro, M.D. Gálvez, J. Falcone, M. Russo, A. Karaiskos, I. Trecarichi, E.M. Losito, A.R. García-Vázquez, E. Gómez, J. Roilides, E. Iosifidis, E. Pournaras, S. Prim, N. Navarro, F. Mirelis, B. Origüen, J. Juan, R.S. Fernández-Ruiz, M. Almela, M. de la Calle, C. Martínez, J.A. Morata, L. Larrosa, N. Puig-Asensio, M. Bou, G. Molina, J. González, V. Bermejo, J. Rucci, V. de Gopegui, E.R. Marinescu, C.I. Fariñas, M.C. Cano, M.E. Gozalo, M. Paño-Pardo, J.R. Mora-Rillo, M. Gómez-Zorrilla, S. Tubau, F. Tsakris, A. Zarkotou, O. Antoniadou, A. Poulakou, G. Souli, M. Lowman, W. Virmani, D. Torre-Cisneros, J. Machuca, I. Gracia-Ahufinger, I. Azap, Ö.K. Helvaci, Ö. Sahin, A.O. Cantón, R. Pintado, V. Bartoletti, M. Giannella, M. Peter, S. Hamprecht, A. Badia, C. Xercavins, M. Fontanals, D. Jové, E. ESGBIS/REIPI/INCREMENT Group
- Abstract
We describe regional differences in therapy for bloodstream infection (BSI) caused by extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL-E) or carbapenemase-producing Enterobacteriaceae (CPE). Patients (n = 1482) in 12 countries from an observational study of BSI caused by ESBL-E or CPE were included. Multivariate logistic regression was used to calculate adjusted odds ratios (aORs) for the influence of country of recruitment on empirical use of β-lactam/β-lactamase inhibitors (BLBLIs) or carbapenems, targeted use of BLBLIs for ESBL-E and use of targeted combination therapy for CPE. Compared with Spain, BLBLI use for empirical therapy was least likely in sites from Israel (aOR 0.34, 95% CI 0.14–0.81), Greece (aOR 0.49, 95% CI 0.26–0.94) and Canada (aOR 0.31, 95% CI 0.11–0.88) but more likely in Italy (aOR 1.58, 95% CI 1.11–2.25) and Turkey (aOR 2.09, 95% CI 1.14–3.81). Empirical carbapenem use was more likely in sites from Taiwan (aOR 1.73, 95% CI 1.03–2.92) and USA (aOR 1.89, 95% CI 1.05–3.39) and less likely in Italy (aOR 0.44, 95% CI 0.28–0.69) and Canada (aOR 0.10, 95% CI 0.01–0.74). Targeted BLBLIs for ESBL-E was more likely in Italian sites. Treatment at sites within Israel, Taiwan, Turkey and Brazil was associated with less combination therapy for CPE. Although this study does not provide precise data on the relative prevalence of ESBL-E or CPE, significant variation in therapy exists across countries even after adjustment for patient factors. Better understanding of what influences therapeutic choices for these infections will aid antimicrobial stewardship efforts. © 2017 Elsevier B.V. and International Society of Chemotherapy
- Published
- 2017
20. Geographical variation in therapy for bloodstream infections due to multidrug-resistant enterobacteriaceae: a post hoc analysis of the INCREMENT study
- Author
-
Patrick N.A. Harris, M. Diletta Pezzani, Belén Gutiérrez-Gutiérrez, Pierluigi Viale, Po-Ren Hsueh, Patricia Ruiz-Garbajosa, Mario Venditti, Mario Tumbarello, Carolina Navarro-Francisco, Esther Calbo, Murat Akova, Helen Giamarellou, Antonio Oliver, Benito Almirante, Oriol Gasch, Luis Martínez-Martínez, Mitchell J. Schwaber, George Daikos, Johann Pitout, Carmen Peña, Alicia Hernández-Torres, Yohei Doi, Federico Pérez, Felipe Francisco Tuon, Evelina Tacconelli, Yehuda Carmeli, Robert A. Bonomo, Álvaro Pascual, David L. Paterson, Jesús Rodríguez-Baño, M.D. del Toro, J. Gálvez, M. Falcone, A. Russob, I. Karaiskos, E.M. Trecarichi, A.R. Losito, E. García-Vázquez, J. Gómez, E. Roilides, E. Iosifidis, S. Pournaras, N. Prim, F. Navarro, B. Mirelis, J. Origüen, R. San Juan, M. Fernández-Ruiz, M. Almela, C. de la Calle, J.A. Martínez, L. Morata, N. Larrosa, M. Puig-Asensio, G. Bou, J. Molina, V. González, J. Bermejo, V. Rucci, E. Ruiz de Gopegui, C.I. Marinescu, M.C. Fariñas, M.E. Cano, M. Gozalo, J.R. Paño-Pardo, Marta Mora-Rillo, S. Gómez-Zorrilla, F. Tubau, A. Tsakris, O. Zarkotou, A. Antoniadou, G. Poulakou, M. Souli, W. Lowman, D. Virmani, Julian Torre-Cisneros, I. Machuca, Irene Gracia-Ahufinger, Ö.K. Azap, Ö. Helvaci, A.O. Sahin, R. Cantón, V. Pintado, M. Bartoletti, M. Giannella, S. Peter, A. Hamprecht, C. Badia, M. Xercavins, D. Fontanals, E. Jové, Universidad de Cantabria, Harris, Patrick N.A., Pezzani, M. Diletta, Gutiérrez-Gutiérrez, Belén, Viale, Pierluigi, Hsueh, Po-Ren, Ruiz-Garbajosa, Patricia, Venditti, Mario, Tumbarello, Mario, Navarro-Francisco, Carolina, Calbo, Esther, Akova, Murat, Giamarellou, Helen, Oliver, Antonio, Almirante, Benito, Gasch, Oriol, Martínez-Martínez, Lui, Schwaber, Mitchell J., Daikos, George, Pitout, Johann, Peña, Carmen, Hernández-Torres, Alicia, Doi, Yohei, Pérez, Federico, Tuon, Felipe Francisco, Tacconelli, Evelina, Carmeli, Yehuda, Bonomo, Robert A., Pascual, Álvaro, Paterson, David L., Rodríguez-Baño, Jesú, del Toro, M.D., Gálvez, J., Falcone, M., Russo, A., Karaiskos, I., Trecarichi, E.M., Losito, A.R., García-Vázquez, E., Gómez, J., Roilides, E., Iosifidis, E., Pournaras, S., Prim, N., Navarro, F., Mirelis, B., Origüen, J., Juan, R. San, Fernández-Ruiz, M., Almela, M., de la Calle, C., Martínez, J.A., Morata, L., Larrosa, N., Puig-Asensio, M., Bou, G., Molina, J., González, V., Bermejo, J., Rucci, V., de Gopegui, E. Ruiz, Marinescu, C.I., Fariñas, M.C., Cano, M.E., Gozalo, M., Paño-Pardo, J.R., Mora-Rillo, Marta, Gómez-Zorrilla, S., Tubau, F., Tsakris, A., Zarkotou, O., Antoniadou, A., Poulakou, G., Souli, M., Lowman, W., Virmani, D., Torre-Cisneros, Julian, Machuca, I., Gracia-Ahufinger, Irene, Azap, Ã .K., Helvaci, Ã ., Sahin, A.O., Cantón, R., Pintado, V., Bartoletti, M., Giannella, M., Peter, S., Hamprecht, A., Badia, C., Xercavins, M., Fontanals, D., and Jové, E.
- Subjects
Male ,0301 basic medicine ,Carbapenem ,Global Health ,Logistic regression ,0302 clinical medicine ,Drug Resistance, Multiple, Bacterial ,Antimicrobial stewardship ,Pharmacology (medical) ,030212 general & internal medicine ,Aged, 80 and over ,Enterobacteriaceae Infections ,General Medicine ,Middle Aged ,Extended-spectrum beta-lactamase ,Klebsiella pneumoniae ,Infectious Diseases ,Beta-lactam/beta-lactamase inhibitors ,Female ,beta-Lactamase Inhibitors ,medicine.drug ,Adult ,Microbiology (medical) ,medicine.medical_specialty ,Combination therapy ,β-Lactam/β-lactamase inhibitor ,030106 microbiology ,Infectious Disease ,Biology ,beta-Lactams ,Carbapenemase ,03 medical and health sciences ,Extended-spectrum β-lactamase ,Enterobacteriaceae ,Sepsis ,Post-hoc analysis ,medicine ,Escherichia coli ,Humans ,Aged ,Retrospective Studies ,Carbapenems ,β-Lactam/β-lactamase inhibitor ,Odds ratio ,biochemical phenomena, metabolism, and nutrition ,Extended-spectrum β-lactamase ,Surgery ,Multiple drug resistance ,Observational study ,Demography - Abstract
We aimed to describe regional differences in therapy for bloodstream infection (BSI) caused by extended-spectrum ?-lactamase-producing Enterobacteriaceae (ESBL-E) or carbapenemase-producing Enterobacteriaceae (CPE). 1,482 patients in 12 countries were included from an observational study of BSI caused by ESBL-E or CPE. Multivariate logistic regression was used to calculate adjusted odds ratios (aORs) for the influence of country of recruitment on empirical use of ?-lactam/?-lactamase inhibitors (BLBLI) or carbapenems, targeted use of BLBLI for ESBL-E and use of targeted combination therapy for CPE. The use of BLBLI for empirical therapy was least likely in sites from Israel (aOR 0.34, 95% CI 0.14-0.81), Greece (aOR 0.49, 95% CI 0.26-0.94) and Canada (aOR 0.31, 95% CI 0.11-0.88) but more likely in Italy (aOR 1.58, 95% CI 1.11-2.2) and Turkey (aOR 2.09, 95% CI 1.14-3.81), compared to Spain as a reference. Empirical carbapenems were more likely to be used in sites from Taiwan (aOR 1.73, 95% CI 1.03-2.92) and USA (aOR 1.89; 95% CI 1.05-3.39), and less likely in Italy (aOR 0.44, 95% CI 0.28-0.69) and Canada (aOR 0.10, 95% CI 0.01-0.74). Targeted BLBLI for ESBL-E was more likely in sites from Italy. Treatment at sites within Israel, Taiwan, Turkey and Brazil was associated with less combination therapy for CPE. Although this study does not provide precise data on the relative prevalence of ESBL-E or CPE, significant variation in therapy exists across countries even after adjustment for patient factors. A better understanding of what influences therapeutic choices for these infections will aid antimicrobial stewardship efforts. PH is supported by an Australian Postgraduate Award from the University of Queensland. The study was funded by the Ministerio de Economía y Competitividad, Instituto de Salud Carlos III - co-financed by European Development Regional Fund "A way to achieve Europe" ERDF, Spanish Network for the Research in Infectious Diseases (REIPI RD12/0015). BGG, JRB, APH and YC also received funds from the COMBACTE-CARE project (grant agreement 115620), Innovative Medicines Initiative (IMI), the European Union's Seventh Framework Programme (FP7/2007-2013) and in-kind contributions from EFPIA companies.
- Published
- 2017
21. Evaluation of the possible influence of trailing and paradoxical effects on the clinical outcome of patients with candidemia
- Author
-
C. Rueda, M. Puig-Asensio, J. Guinea, B. Almirante, M. Cuenca-Estrella, O. Zaragoza, B. Padilla, P. Muñoz, J.R. Paño Pardo, J. García-Rodríguez, C. García Cerrada, J. Fortún, P. Martín, E. Gómez, P. Ryan, C. Campelo, I. de los Santos Gil, V. Buendía, B.P. Gorricho, M. Alonso, F.S. Sanz, J.M. Aguado, P. Merino, F. González Romo, M. Gorgolas, I. Gadea, J.E. Losa, A. Delgado-Iribarren, A. Ramos, Y. Romero, I. Sánchez Romero, J. Rodriguez-Baño, A. Isabel Suarez, A. Loza, A.I. Aller García, E. Martín-Mazuelos, M.R. Pérez de Pipaón, J. Garnacho, C. Ortiz, M. Chávez, F.L. Maroto, M. Salavert, J. Pemán, J. Blanquer, D. Navarro, J.J. Camarena, R. Zaragoza, V. Abril, C. Gimeno, S. Hernáez, G. Ezpeleta, E. Bereciartua, J.L. Hernández Almaraz, M. Montejo, R.A. Rivas, R. Ayarza, A.M. Planes, I.R. Camps, J. Mensa, M. Almela, M. Gurgui, F. Sánchez-Reus, J. Martinez-Montauti, M. Sierra, J.P. Horcajada, L. Sorli, J. Gómez, A. Gené, M. Urrea, M. Valerio, A. Díaz-Martín, F. Puchades, A. Mularoni, Instituto de Salud Carlos III, Ministerio de Economía y Competitividad (España), Gilead Sciences, MSD, Astellas Pharma, Pfizer, European Commission, Fundación SEIMC-GESIDA, Red Española de Investigación en Patología Infecciosa, bioMérieux, Merck Sharp & Dohme de España, Fundación Francisco Soria Melguizo, Ferrer, Ministerio de Asuntos Exteriores y Cooperación (España), Ministerio de Educación y Cultura (España), Ministerio de Sanidad, Servicios Sociales e Igualdad (España), Fundación Ramón Areces, Fundación Mutua Madrileña, and Schering-Plough
- Subjects
0301 basic medicine ,Microbiology (medical) ,Azoles ,Aging ,medicine.medical_specialty ,Antifungal Agents ,030106 microbiology ,Population ,Gastroenterology ,Cohort Studies ,Candida tropicalis ,03 medical and health sciences ,Minimum inhibitory concentration ,Echinocandins ,Species Specificity ,Drug Resistance, Fungal ,Internal medicine ,Odds Ratio ,medicine ,Humans ,education ,Candida ,education.field_of_study ,biology ,Candidemia ,General Medicine ,Odds ratio ,biology.organism_classification ,Confidence interval ,Surgery ,Treatment Outcome ,030104 developmental biology ,Infectious Diseases ,Trailing effect ,Paradoxical growth ,Fluconazole ,medicine.drug ,Blood sampling - Abstract
CANDIPOP Project from GEIH-GEMICOMED (SEIMC) and REIPI: B. Padilla, P. Muñoz, J. Guinea, J. R. Paño Pardo, J. García-Rodríguez, C. García Cerrada, J. Fortún, P. Martín, E. Gómez, P. Ryan, C. Campelo, I. de los Santos Gil, V. Buendía, B. P. Gorricho, M. Alonso, F. S. Sanz, J. M. Aguado, P. Merino, F. González Romo, M. Gorgolas, I. Gadea, J. E. Losa, A. Delgado-Iribarren, A. Ramos, Y. Romero, I. Sánchez Romero, O. Zaragoza, M. Cuenca-Estrella, J. Rodriguez-Baño, A. Isabel Suarez, A. Loza, A. I. Aller García, E. Martín-Mazuelos, M. R. Pérez de Pipaón, J. Garnacho, C. Ortiz, M. Chávez, F. L. Maroto, M. Salavert, J. Pemán, J. Blanquer, D. Navarro, J. J. Camarena, R. Zaragoza, V. Abril, C. Gimeno, S. Hernáez, G. Ezpeleta, E. Bereciartua, J. L. Hernández Almaraz, M. Montejo, R. A. Rivas, R. Ayarza, A. M. Planes, I. R. Camps, B. Almirante, J. Mensa, M. Almela, M. Gurgui, F. Sánchez-Reus, J. Martinez-Montauti, M. Sierra, J. P. Horcajada, L. Sorli, J. Gómez, A. Gené, M. Urrea, M. Valerio, A. Díaz-Martín, F. Puchades, A. Mularoni., [Objective] Paradoxical growth (PG) and trailing effect (TE) are frequently observed during antifungal susceptibility testing (AFST). These two phenomena interfere with the determination of the minimal inhibitory concentration (MIC). The aim of this study was to assess the clinical impact of TE and PG., [Methods] We analysed the frequency of TE and PG of 690 Candida isolates collected from a population-based study performed in Spain (CANDIPOP) and correlated the results with clinical outcome of the patients., [Results] Around 70% (484/690) of the isolates exhibited TE to azoles. Candida tropicalis showed the highest presence of TE (39/53 isolates exhibited residual growth >25% of control). No TE was seen in most of the isolates from the psilosis complex. PG was mainly associated with echinocandins. In patients treated with fluconazole within the first 48 hours after blood sampling (n = 221), the presence of TE to azoles tended to be associated with lower 30-day mortality (odds ratio (OR) 0.55, 95% confidence interval (CI) 0.25–1.00) but not with clinical failure (OR 0.85, 95% CI 0.45–1.54). In the subgroup of 117 patients treated with echinocandins, the presence of PG was not associated with patient's response to antifungal treatment (OR for 30-day mortality 1.63, 95% CI 0.76–4.03; OR for clinical failure 1.17, 95% CI 0.53–2.70)., [Conclusions] TE or PG are widely expressed among Candida spp., although they do not seem to influence clinical outcome., C. Rueda was funded by a Sara Borrell contract from the Fondo de Investigaciones Sanitarias (FIS, reference number CD11/00110). O. Zaragoza was funded by grant SAF2014-54336-R from the Spanish Ministry for Economics and Competitivity. The CANDIPOP study was funded by research grants from Gilead, MSD, Astellas and Pfizer and by funding from the Fundacion SEIMC-GESIDA and the Ministerio de Economía y Competitividad, Instituto de Salud Carlos III, cofinanced by the European Development Regional Fund ‘A way to achieve Europe’ ERDF and the Spanish Network for the Research in Infectious Diseases (REIPI RD12/0015). MC-E has received grant support from Astellas Pharma, bioMerieux, Gilead Sciences, Merck Sharp & Dohme, Pfizer, Schering-Plough, Soria Melguizo SA, Ferrer International, the Europea Union, the ALBAN program, the Spanish Agency for International Cooperation, the Spanish Ministry of Culture and Education, the Spanish Health Research Fund, the Instituto de Salud Carlos III (Spanish Ministry of Economy and Competitiveness), the Ramón Areces Foundation and the Mutua Madrileña Foundation.
- Published
- 2017
22. Daptomycin Is Effective for Treatment of Experimental Endocarditis Due to Methicillin-Resistant and Glycopeptide-Intermediate Staphylococcus epidermidis
- Author
-
C, García-de-la-Mària, F, Marco, Y, Armero, D, Soy, A, Moreno, A, del Río, M, Almela, C, Cervera, S, Ninot, C, Falces, C A, Mestres, J M, Gatell, M T, Jiménez de Anta, J M, Miró, and E, de Lazzari
- Subjects
medicine.drug_class ,Antibiotics ,Microbial Sensitivity Tests ,medicine.disease_cause ,Microbiology ,Daptomycin ,Vancomycin ,Staphylococcus epidermidis ,medicine ,Animals ,Humans ,Endocarditis ,Experimental Therapeutics ,Pharmacology (medical) ,Antibacterial agent ,Pharmacology ,biology ,Glycopeptides ,biochemical phenomena, metabolism, and nutrition ,Staphylococcal Infections ,medicine.disease ,biology.organism_classification ,Infectious Diseases ,Staphylococcus aureus ,Infective endocarditis ,Methicillin Resistance ,Rabbits ,medicine.drug - Abstract
This study evaluated the daptomycin activity against two methicillin-resistant Staphylococcus epidermidis (MRSE) clinical isolates with different vancomycin susceptibilities: MRSE-375, with a vancomycin MIC of 2 μg/ml, and NRS6, a glycopeptide-intermediate S. epidermidis (GISE) strain with a vancomycin MIC of 8 μg/ml. The in vivo activity of daptomycin at two different doses (standard dose [SD-daptomycin], 6 mg/kg of body weight/day intravenously [i.v.]; high dose [HD-daptomycin], 10 mg/kg/day i.v.) was evaluated in a rabbit model of infective endocarditis and compared with that of a standard dose of vancomycin (SD-vancomycin; 1 g i.v. every 12 h) for 2 days. For the MRSE-375 strain, high-dose vancomycin (HD-vancomycin; 1 g i.v. every 6 h) was also studied. For MRSE-375, SD- and HD-daptomycin therapy sterilized significantly more vegetations than SD-vancomycin therapy (9/15 [60%] and 11/15 [73%] vegetations, respectively, versus 3/16 [19%] vegetations; P = 0.02 and P = 0.002, respectively). HD-daptomycin sterilized more vegetations than HD-vancomycin (11/15 [73%] versus 5/15 [33%] vegetations; P = 0.03) and was more effective than SD- and HD-vancomycin in reducing the density of bacteria in valve vegetations (0 log 10 CFU/g vegetation [interquartile range {IQR}, 0 to 1 log 10 CFU/g vegetation] versus 2 log 10 CFU/g vegetation [IQR, 2 to 2 log 10 CFU/g vegetation] and 2 log 10 CFU/g vegetation [IQR, 0 to 2.8 log 10 CFU/g vegetation]; P = 0.002 and P = 0.01, respectively). For the NRS6 strain, SD- and HD-daptomycin were significantly more effective than vancomycin in reducing the density of bacteria in valve vegetations (3.7 log 10 CFU/g vegetation [IQR, 2 to 6 log 10 CFU/g vegetation] versus 7.1 log 10 CFU/g vegetation [IQR, 5.2 to 8.5 log 10 CFU/g vegetation]; P = 0.02). In all treatment arms, isolates recovered from vegetations remained susceptible to daptomycin and vancomycin and had the same MICs. In conclusion, daptomycin at doses of 6 mg/kg/day or 10 mg/kg/day is more effective than vancomycin for the treatment of experimental endocarditis due to MRSE and GISE.
- Published
- 2010
- Full Text
- View/download PDF
23. Pharmacokinetics of danofloxacin after single dose intravenous, intramuscular and subcutaneous administration to loggerhead turtles Caretta caretta
- Author
-
A. Bayón, Elisa Escudero, P. Marín, E. Fernández-Varón, Ramón M. Almela, C. M. Cárceles, and Cristina Clavel
- Subjects
Male ,medicine.drug_class ,Danofloxacin ,Injections, Subcutaneous ,Antibiotics ,Biological Availability ,Aquatic Science ,Pharmacology ,Biology ,Injections, Intramuscular ,High-performance liquid chromatography ,Pharmacokinetics ,medicine ,Animals ,Ecology, Evolution, Behavior and Systematics ,Volume of distribution ,Cross-Over Studies ,Half-life ,Crossover study ,Anti-Bacterial Agents ,Turtles ,Bioavailability ,Area Under Curve ,Anesthesia ,Injections, Intravenous ,Female ,Fluoroquinolones ,Half-Life ,medicine.drug - Abstract
The single-dose disposition kinetics of the antibiotic danofloxacin were determined in clinically normal loggerhead turtles (n = 6) after intravenous (IV), subcutaneous (SC) and intramuscular (IM) administration of 6 mg kg(-1) bodyweight. Danofloxacin concentrations were determined by high performance liquid chromatography with fluorescence detection. The concentration-time data were analyzed by non-compartmental kinetic methods. Steady-state volume of distribution, and total body clearance of danofloxacin after IV administration were estimated to be 1.02 +/- 0.17 1 kg(-1) and 0.11 +/- 0.01 1 h(-1) kg(-1), respectively. Following IM and SC administration, danofloxacin achieved maximum plasma concentrations of 10.25 +/- 4.59 and 10.35 +/- 4.45 mg l(-1) at 1.20 +/- 0.52 and 1.46 +/- 0.48 h, respectively. The absolute bioavailabilities after SC and IM routes were 98.72 +/- 11.73 and 104.81 +/- 14.97%, respectively. Danofloxacin shows a favourable pharmacokinetic profile in loggerhead turtles reflected by parameters such as a long half-life and a high bioavailability following a single dose of 6 mg kg(-1) by IM and SC routes; thus, it is likely that this treatment will be effective in loggerhead turtles with bacterial infections.
- Published
- 2008
- Full Text
- View/download PDF
24. Subcutaneous extraskeletal osteosarcoma in a metatarsal footpad in a cat
- Author
-
Agustina Ansón, Ramón M. Almela, Wolf von Bomhard, and Ursula Mayer
- Subjects
Extraskeletal Osteosarcoma ,Pathology ,medicine.medical_specialty ,General Veterinary ,medicine.diagnostic_test ,040301 veterinary sciences ,business.industry ,Domestic Short Hair Cat ,04 agricultural and veterinary sciences ,Thigh ,medicine.disease ,0403 veterinary science ,03 medical and health sciences ,0302 clinical medicine ,medicine.anatomical_structure ,Primary bone ,030220 oncology & carcinogenesis ,Biopsy ,medicine ,Osteosarcoma ,Metatarsal bones ,Differential diagnosis ,business - Abstract
Background Extraskeletal osteosarcomas (ESOSAs) are rare neoplasms in humans and animals. In cats, ESOSA has been reported to arise from orbital, ocular, intestinal, mammary and subcutaneous locations. Subcutaneous ESOSA occurs most commonly at sites used for vaccination including interscapular, dorsal lumbar or thigh areas. Previous reports of feline cases have not documented the use of advanced diagnostic imaging to exclude a primary bone tumour. Objective To describe the clinicopathological and advanced imaging findings of a subcutaneous ESOSA occurring in a metatarsal footpad of a cat and to report the one year follow-up status. Animal A 9-year-old neutered male domestic short hair cat. Methods Physical, abdominal ultrasonographic and computed tomographic examinations, and excisional biopsy for histopathological and immunohistochemical evaluation. Results The cat presented with mild focal erythematous swelling of the left metatarsal pad. ESOSA was diagnosed through advanced diagnostic imaging and histopathological examinations. Histopathological findings were consistent with osteosarcoma. No primary bone disease was observed on computed tomography. The owners declined limb amputation. One year after diagnosis, the cat was alive without disease progression. Conclusions and clinical importance Extraskeletal osteosarcoma should be considered in the differential diagnosis of soft tissue swelling in footpads in cats. Advanced diagnostic imaging is recommended to exclude primary bone tumours.
- Published
- 2017
- Full Text
- View/download PDF
25. Empirical and targeted therapy of candidemia with fluconazole versus echinocandins: a propensity score–derived analysis of a population-based, multicentre prospective cohort
- Author
-
L.E. López-Cortés, B. Almirante, M. Cuenca-Estrella, J. Garnacho-Montero, B. Padilla, M. Puig-Asensio, I. Ruiz-Camps, J. Rodríguez-Baño, P. Muñoz, J. Guinea, J.R. Paño Pardo, J. García-Rodríguez, C. García Cerrada, J. Fortún, P. Martín, E. Gómez, P. Ryan, C. Campelo, I. de los Santos Gil, V. Buendía, B. Pérez Gorricho, M. Alonso, F. Sanz Sanz, J. María Aguado, P. Merino, F. González Romo, M. Gorgolas, I. Gadea, J.E. Losa, A. Delgado-Iribarren, A. Ramos, Y. Romero, I. Sánchez Romero, O. Zaragoza, A.I. Suarez, A. Loza, A.I. Aller García, E. Martín-Mazuelos, M.R. Pérez de Pipaón, J. Garnacho, C. Ortiz, M. Chávez, F.L. Maroto, M. Salavert, J. Pemán, J. Blanquer, D. Navarro, J.J. Camarena, R. Zaragoza, V. Abril, C. Gimeno, S. Hernáez, G. Ezpeleta, E. Bereciartua, J.L. Hernández Almaraz, M. Montejo, R.A. Rivas, R. Ayarza, A.M. Planes, I. Ruiz Camps, J. Mensa, M. Almela, M. Gurgui, F. Sánchez-Reus, J. Martinez-Montauti, M. Sierra, J.P. Horcajada, L. Sorli, J. Gómez, A. Gené, M. Urrea, M. Valerio, A. Díaz-Martín, F. Puchades, A. Mularoni, [Lopez-Cortes, L. E.] Hosp Univ Virgen Macarena, Unidad Clin Enfermedades Infecciosas Microbiol &, IBiS, Seville, Spain, [Rodriguez-Bano, J.] Hosp Univ Virgen Macarena, Unidad Clin Enfermedades Infecciosas Microbiol &, IBiS, Seville, Spain, [Lopez-Cortes, L. E.] Hosp Univ Virgen del Rocio, Unidad Clin Enfermedades Infecciosas Microbiol &, IBiS, Seville, Spain, [Rodriguez-Bano, J.] Hosp Univ Virgen del Rocio, Unidad Clin Enfermedades Infecciosas Microbiol &, IBiS, Seville, Spain, [Almirante, B.] Univ Autonoma Barcelona, Hosp Univ Vall dHebron, Dept Infect Dis, Barcelona, Spain, [Puig-Asensio, M.] Univ Autonoma Barcelona, Hosp Univ Vall dHebron, Dept Infect Dis, Barcelona, Spain, [Ruiz-Camps, I.] Univ Autonoma Barcelona, Hosp Univ Vall dHebron, Dept Infect Dis, Barcelona, Spain, [Cuenca-Estrella, M.] Inst Salud Carlos III, Spanish Natl Ctr Microbiol, Dept Micol, Madrid, Spain, [Garnacho-Montero, J.] Hosp Univ Virgen Macarena, Unidad Clin Cuidados Intens, Seville, Spain, [Padilla, B.] Hosp Gen Univ Gregorio Maranon, Dept Clin Microbiol & Infect Dis, Madrid, Spain, [Rodriguez-Bano, J.] Univ Seville, Dept Med, Seville, Spain, Gilead Sciences, Pfizer, Instituto de Salud Carlos III, Astellas Pharma, bioMerieux, Merck Sharp and Dohme, Schering Plough, Soria Melguizo SA, Ferrer International, European Union, ALBAN programme, Spanish Agency for International Cooperation, Spanish Ministry of Culture and Education, Spanish Health Research Fund, Ramon Areces Foundation, Mutua Madrilena Foundation, Merck Sharp & Dohme de España, Novartis, bioMérieux, Schering-Plough, Fundación Francisco Soria Melguizo, European Commission, Ministerio de Asuntos Exteriores y Cooperación (España), Ministerio de Educación y Cultura (España), Ministerio de Sanidad, Servicios Sociales e Igualdad (España), Fundación Ramón Areces, and Fundación Mutua Madrileña
- Subjects
Male ,0301 basic medicine ,Identification ,Antifungal Agents ,Epidemiology ,Resistance ,Comorbidity ,Kaplan-Meier Estimate ,Anidulafungin ,Targeted therapy ,Echinocandins ,0302 clinical medicine ,030212 general & internal medicine ,Blood-stream infections ,Prospective cohort study ,Fluconazole ,education.field_of_study ,Surveillance ,Hazard ratio ,General Medicine ,Middle Aged ,Invasive candidiasis ,Treatment Outcome ,Impact ,Infectious Diseases ,Population Surveillance ,Female ,Cohort study ,medicine.drug ,Microbiology (medical) ,medicine.medical_specialty ,030106 microbiology ,Population ,Outcomes ,Bloodstream infection ,03 medical and health sciences ,Internal medicine ,medicine ,Humans ,Antifungal treatment ,Mortality ,Propensity Score ,education ,Aged ,Proportional Hazards Models ,business.industry ,Proportional hazards model ,Candidemia ,bacterial infections and mycoses ,Empirical therapy ,Confidence interval ,Surgery ,Bloodstream infections ,business - Abstract
CANDIPOP Project from GEIH-GEMICOMED (SEIMC) and REIPI., We compared the clinical efficacy of fluconazole and echinocandins in the treatment of candidemia in real practice. The CANDIPOP study is a prospective, population-based cohort study on candidemia carried out between May 2010 and April 2011 in 29 Spanish hospitals. Using strict inclusion criteria, we separately compared the impact of empirical and targeted therapy with fluconazole or echinocandins on 30-day mortality. Cox regression, including a propensity score (PS) for receiving echinocandins, stratified analysis on the PS quartiles and PS-based matched analyses, were performed. The empirical and targeted therapy cohorts comprised 316 and 421 cases, respectively; 30-day mortality was 18.7% with fluconazole and 33.9% with echinocandins (p 0.02) in the empirical therapy group and 19.8% with fluconazole and 27.7% with echinocandins (p 0.06) in the targeted therapy group. Multivariate Cox regression analysis including PS showed that empirical therapy with fluconazole was associated with better prognosis (adjusted hazard ratio 0.38; 95% confidence interval 0.17–0.81; p 0.01); no differences were found within each PS quartile or in cases matched according to PS. Targeted therapy with fluconazole did not show a significant association with mortality in the Cox regression analysis (adjusted hazard ratio 0.77; 95% confidence interval 0.41–1.46; p 0.63), in the PS quartiles or in PS-matched cases. The results were similar among patients with severe sepsis and septic shock. Empirical or targeted treatment with fluconazole was not associated with increased 30-day mortality compared to echinocandins among adults with candidemia., BA has received grant support from Gilead Sciences, Pfizer and the Instituto de Salud Carlos III, and he has received honoraria for talks on behalf of Gilead Sciences, Merck Sharp and Dohme, Pfizer, Astellas and Novartis. MCE has received grant support from Astellas Pharma, bioMerieux, Gilead Sciences, Merck Sharp and Dohme, Pfizer, Schering Plough, Soria Melguizo SA, Ferrer International, the European Union, the ALBAN programme, the Spanish Agency for International Cooperation, the Spanish Ministry of Culture and Education, the Spanish Health Research Fund, the Instituto de Salud Carlos III, the Ramon Areces Foundation and the Mutua Madrileña Foundation. MCE has received grant support from Astellas Pharma, bioMerieux, Gilead Sciences, Merck Sharp and Dohme, Pfizer, Schering Plough, Soria Melguizo SA, Ferrer International, the European Union, the ALBAN programme, the Spanish Agency for International Cooperation, the Spanish Ministry of Culture and Education, the Spanish Health Research Fund, the Instituto de Salud Carlos III, the Ramon Areces Foundation and the Mutua Madrileña Foundation.
- Published
- 2016
- Full Text
- View/download PDF
26. Analysis of Factors Influencing the Outcome and Development of Septic Metastasis or Relapse in Salmonella Bacteremia
- Author
-
J. Galofre, A. Moreno, J. Mensa, J. M. Miro, J. M. Gatell, M. Almela, X. Claramonte, L. Lozano, A. Trilla, J. Mallolas, M. T. J. de Anta, and E. Soriano
- Subjects
Adult ,Male ,Microbiology (medical) ,medicine.medical_specialty ,Salmonella ,Adolescent ,Salmonella enteritidis ,medicine.medical_treatment ,Population ,Bacteremia ,medicine.disease_cause ,Gastroenterology ,Recurrence ,Internal medicine ,White blood cell ,medicine ,Humans ,Prospective Studies ,education ,Aged ,Aged, 80 and over ,education.field_of_study ,Leukopenia ,Septic shock ,business.industry ,Immunosuppression ,Middle Aged ,medicine.disease ,Infectious Diseases ,medicine.anatomical_structure ,Salmonella Infections ,Immunology ,Female ,medicine.symptom ,business - Abstract
One-hundred seventy-two consecutive adult patients with salmonella bacteremia documented by at least one positive blood culture were prospectively evaluated over a 10-year period. Salmonella enteritidis was isolated in 121 cases (70.3%), Salmonella typhimurium in 29 (16.9%), and other Salmonella species in 22 (12.8%). Twenty-seven patients (15.7%) developed septic metastasis; 21 patients (12.2%) died of bacteremia, and 24 (16.7%) of the 144 patients who survived had at least one relapse. A logistic regression analysis selected three variables as independently influencing outcome: septic shock (P = .005), coma (P = .029), and immunosuppression (P = .04). By means of the same statistical analysis, leukopenia (a white blood cell count of < 4 x 10(9)/L) was identified as an independent risk factor for relapse (P < .0001). The possibility of salmonella bacteremia must be considered when immunosuppressed patients have fever and no obvious source of infection. Treatment with a drug active against Salmonella species is essential in this population. Patients with leukopenia should be considered as recipients of prophylaxis for relapse.
- Published
- 1994
- Full Text
- View/download PDF
27. Effect of surface modifications of leather on its joint strength with polyvinyl chloride
- Author
-
M. Almela, Teresa del Pilar Ferrándiz-Gómez, J.M. Martín-Martínez, A.C. Orgilés-Barceló, and F. Maldonado
- Subjects
Materials science ,technology, industry, and agriculture ,Surfaces and Interfaces ,General Chemistry ,Surfaces, Coatings and Films ,Polyvinyl chloride ,chemistry.chemical_compound ,chemistry ,Pulmonary surfactant ,Mechanics of Materials ,Collagen fibres ,Lyotropic ,otorhinolaryngologic diseases ,Materials Chemistry ,Urea ,Wetting ,Composite material ,Joint (geology) ,Shrinkage - Abstract
The treatment of bovine leathers with wetting and lyotropic agents followed by heating produced a strengthening of the leathers which increased their joint strength properties to polyvinyl chloride (PVC). A cohesive failure of leather was always obtained. The highest cohesive strength (or point peel strength) was obtained when the treatment was carried out at 140°C with the surfactant NFOE (8.5) (nonylphenol polyoxyethylene with 8.5 mol of oxyethylene). The lyotropic agents (CaCl2, urea) gave very high values (a five-fold increase), whereas the water-dimethyl ketone blends and pure water resulted in a smaller improvement in cohesive strength (a three-fold increase). The improved cohesive strength of leather was mainly due to the destruction of the ordered structure of collagen fibres and to the creation of a complex entanglement network among the collagen fibres. The treatments applied to a bovine leather produced a shrinkage of 65%; the degree of shrinkage was not a function of the kind of treatment, but...
- Published
- 1994
- Full Text
- View/download PDF
28. Genetic assessment, illegal trafficking and management of the Mediterranean spur-thighed tortoise in Southern Spain and Northern Africa
- Author
-
Laura Altet, I. Burguete, Maria Salinas, A. Bayón, Armand Sánchez, Cristina Clavel, Ramón M. Almela, Gobierno de la Región de Murcia, World Wildlife Fund, Fundación Global Nature, Ministerio de Economía y Competitividad (España), and Fundación Séneca
- Subjects
education.field_of_study ,Tortoise ,biology ,Ecology ,Population ,Biodiversity ,Endangered species ,biology.organism_classification ,Mediterranean Basin ,Habitat destruction ,Genetics ,Biological dispersal ,education ,Testudo graeca ,Ecology, Evolution, Behavior and Systematics - Abstract
Wild populations of many species are declining as a result of habitat destruction and climate change but also through the over-collection for wild meat and the pet trade. With a long history of trade around the Mediterranean, populations of the spur-thighed tortoise (Testudo graeca graeca) have become highly disturbed. In this study we utilise a molecular approach to investigate the diversity, population admixture and structure of T. g. graeca populations in northern Africa and southern Spain, as well as to obtain an insight into the origin of newly established populations in the south of Europe. We infer this from the sequencing of two partial regions of the mitochondria (12s rRNA + cyt b) and genotyping at 16 microsatellite markers in 448 tortoises. Our results are consistent with the hypothesis that Spanish populations were founded from North Africa, the consequence of multiple introductions or exchanges in genetic material as a result of trans-oceanic dispersal. Despite the trade of individuals between both sides of the Gibraltar Strait, our analysis of population structure showed clear differences between both the African and European populations, suggesting an incipient evolutionary lineage in southeast of Spain. As such, these populations possess unique genetic identities and should be treated as different management units. Surprisingly, the genetic data identified a great deal of diversity contained within pet (captive) stock and also allowed us to infer hybrids among individuals with another species of terrestrial tortoise from northern Spain (T. hermanni hermanni). Additionally, our results provide insight into the local movement and trade of individuals that has occurred around the Mediterranean basin (between northern Africa and southern Spain) and as such provides guidance for the effective management of T. g. graeca captive stock and the illegal trafficking., The authors gratefully acknowledge to Fundación Global Nature (Murcia Region, Spain); the Wildlife Rehabilitation Center “El Valle” (Murcia Region, Spain); Marcos Fernández (Wildlife Rehabilitation Center Santa Faz, Alicante, Spain) and Albert Martinez-Silvestre (CRARC, Barcelona, Spain). Thanks also to Peter Spencer for his revisions of the manuscript and referees for their comments and suggestions that helped to improve the previous manuscript. The financial support was provided by both Fundación Séneca, Spain (Proyect 00655/PI/04) and by MEC, Spain (Grant AP-2004-4048).
- Published
- 2011
29. Addition of gentamicin or rifampin does not enhance the effectiveness of daptomycin in treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureus
- Author
-
J M, Miró, C, García-de-la-Mària, Y, Armero, D, Soy, A, Moreno, A, del Río, M, Almela, M, Sarasa, C A, Mestres, J M, Gatell, M T, Jiménez de Anta, F, Marco, and E, de Lazzari
- Subjects
Methicillin-Resistant Staphylococcus aureus ,medicine.drug_class ,Antibiotics ,Microbial Sensitivity Tests ,Biology ,medicine.disease_cause ,Microbiology ,Daptomycin ,medicine ,polycyclic compounds ,Animals ,Humans ,Pharmacology (medical) ,Experimental Therapeutics ,Antibacterial agent ,Pharmacology ,Aminoglycoside ,Endocarditis, Bacterial ,biochemical phenomena, metabolism, and nutrition ,bacterial infections and mycoses ,Methicillin-resistant Staphylococcus aureus ,Anti-Bacterial Agents ,carbohydrates (lipids) ,Infectious Diseases ,Staphylococcus aureus ,Gentamicin ,lipids (amino acids, peptides, and proteins) ,Rabbits ,Gentamicins ,Rifampicin ,medicine.drug - Abstract
This study evaluated the activity of daptomycin combined with either gentamicin or rifampin against three methicillin-resistant Staphylococcus aureus (MRSA) clinical isolates in vitro and one isolate in vivo against a representative strain (MRSA-572). Time-kill experiments showed that daptomycin was bactericidal against these strains at concentrations over the MIC. Daptomycin at sub-MIC concentrations plus gentamicin at 1× and 2× the MIC yielded synergy, while the addition of rifampin at 2 to 4 μg/ml resulted in indifference (two strains) or antagonism (one strain). The in vivo activity of daptomycin (6 mg/kg of body weight once a day) was evaluated ± gentamicin (1 mg/kg intravenously [i.v.] every 8 h [q8h]) or rifampin (300 mg i.v. q8h) in a rabbit model of infective endocarditis by simulating human pharmacokinetics. Daptomycin plus gentamicin (median, 0 [interquartile range, 0 to 2] log 10 CFU/g vegetation) was as effective as daptomycin alone (0 [0 to 2] log 10 CFU/g vegetation) in reducing the density of bacteria in valve vegetations ( P = 0.83), and both were more effective than daptomycin plus rifampin (3 [2 to 3.5] log 10 CFU/g vegetation; P < 0.05) for the strain studied. In addition, daptomycin sterilized a ratio of vegetations that was similar to that of daptomycin plus gentamicin (10/15 [67%] versus 9/15 [60%]; P = 0.7), and both regimens did so more than daptomycin plus rifampin (3/15 [20%]; P = 0.01 and P = 0.02, respectively). No statistical difference was noted between daptomycin plus gentamicin and daptomycin alone for MRSA treatment. In the combination arm, all isolates from vegetations remained susceptible to daptomycin, gentamicin, and rifampin. Sixty-one percent of the isolates (8/13) acquired resistance to rifampin during monotherapy. In the daptomycin arm, resistance was detected in only one case, in which the daptomycin MIC rose to 2 μg/ml among the recovered bacteria. In conclusion, the addition of gentamicin or rifampin does not enhance the effectiveness of daptomycin in the treatment of experimental endocarditis due to MRSA.
- Published
- 2009
30. Accumulation and tissue distribution of heavy metals and essential elements in loggerhead turtles (Caretta caretta) from Spanish Mediterranean coastline of Murcia
- Author
-
Miguel Motas, J. Talavera, Régulo Ángel Cánovas, Alejandro Ángel Bayón del Río, Silvia Jerez, and Ramón M. Almela
- Subjects
Muscle tissue ,Mediterranean climate ,Central Nervous System ,Environmental Engineering ,Health, Toxicology and Mutagenesis ,Zoology ,chemistry.chemical_element ,Kidney ,Bone and Bones ,Arsenic ,Selenium ,Mediterranean sea ,Dry weight ,Metals, Heavy ,medicine ,Mediterranean Sea ,Environmental Chemistry ,Animals ,Marine ecosystem ,Tissue Distribution ,Cheloniidae ,Skin ,Cadmium ,biology ,Ecology ,Public Health, Environmental and Occupational Health ,General Medicine ,General Chemistry ,Mercury ,biology.organism_classification ,Pollution ,Trace Elements ,Turtles ,Zinc ,medicine.anatomical_structure ,chemistry ,Lead ,Liver ,Spain ,Bioindicator ,Water Pollutants, Chemical ,Environmental Monitoring - Abstract
Sea turtles are of increasing interest as potential bioindicators of the heavy metal pollution in marine ecosystems. In the present work, concentrations of heavy metals and essential elements (As, Cd, Hg, Pb, Se, Zn) in different organs and tissues (liver, kidney, muscle, bone, blood, central nervous system and skin) of loggerhead sea turtles (Caretta caretta) were determined from stranded animals found along the Spanish Mediterranean coastlines of Murcia. Relatively high average levels of As (skin: 52.13 microg g(-1) dry weight; muscle: 40.95 microg g(-1) dry weight), and especially high individual levels of Zn in muscle tissue (1002.4 microg g(-1) dry weight) were detected. Furthermore, a significant degree of organotrophism of Cd was observed in kidney tissue. The concentrations detected, the distribution among the tissues and the differences observed between juvenile and adult specimens are generally compatible with chronic exposure to the elements studied, whilst levels produced by acute exposure were ruled out.
- Published
- 2009
31. The binding of anionic and nonionic surfactants to collagen through the hydrophobic effect
- Author
-
A. Otero, J. Costa-López, M. Almela, and F. Maldonado
- Subjects
Anions ,Chemical Phenomena ,Chemistry, Physical ,Chemistry ,Sodium Dodecyl Sulfate ,Ionic bonding ,Hydrogen-Ion Concentration ,Biochemistry ,Polyethylene Glycols ,Hydrophobic effect ,Surface-Active Agents ,Adsorption ,Pulmonary surfactant ,Chemical engineering ,Collagen metabolism ,Organic chemistry ,Nonionic surfactant ,Collagen ,Fatty Alcohols ,Previously treated - Abstract
The adsorption of nonionic surfactants on hide powder previously treated with anionic surfactants has been studied. The adsorption of nonionic surfactants takes place through hydrophobic interactions. A mechanism has been proposed for this interaction, assuming that the nonionic surfactant has been fixed by means of secondary adsorption (hydrophobic interaction) after the primary adsorption of the anionic surfactant (ionic and hydrophobic interaction) which makes it possible.
- Published
- 1991
- Full Text
- View/download PDF
32. [Methicillin-resistant Staphylococcus aureus bacteremia. Predictor factors for an isolate with a vancomycin minimal inhibitory concentrationor =2 mg/l]
- Author
-
M, Ortega, F, Marco, A, Soriano, M, Almela, J A, Martínez, A, Muñoz, and J, Mensa
- Subjects
Male ,Staphylococcus aureus ,Predictive Value of Tests ,Vancomycin ,Humans ,Bacteremia ,Female ,Methicillin Resistance ,Microbial Sensitivity Tests ,Prospective Studies ,Middle Aged ,Aged ,Anti-Bacterial Agents - Abstract
A greater rate of treatment failures with vancomycin in methicillin-resistant Staphylococcus aureus (MRSA) bacteremia has been reported recently when the minimum inhibitory concentration (MIC) isor =2 mg/l. This study has aimed to evaluate if there are clinical and/or epidemiological factors that predict isolation of a MRSA strain with MIC of vancomycin ofor =2 mg/L in the bacteremia episodes collected during a 15 year period (January 1991 to December 2005) in a tertiary urban hospital. During the study period, a total of 478 episodes of MRSA bacteremia were studied prospectively. The following clinical variables were recorded for each one: age, gender, comorbidity, previous administration of vancomycin or another antibiotic, prognosis of baseline diseases, bacteremia focus, shock, empiric antibiotic received and mortality. The MIC of vancomycin of 419 strains (88%) was determined with the E-test. In 216 (52%) of the isolations the MIC of vancomycin was 1.50 mg/L, in 110 (26%) of the cases it wasor =1 mg/l and in 93 (22%) 2 mg/l. Uni-and multivariate analyses were made, comparing the clinical variables of the patients infected by strains with MIC of vancomycinor =2 mg/l regarding the MIC strainsor =1 mg/l. In the last 3 years of the study (2003-2005) the proportion of the strains with MIC of vancomycinor =2 mg/l was significantly greater than those isolated with MICor = 1 mg/L (44 % vs 3 %; p0.001). In the multivariate analysis, the only clinical characteristic associated independently to the isolation of a strain with MICor =2 mg/l was the nosocomial-acquired infection OR (95 % CI): 1.94 (1.04-3.63); p=0.04. Although the isolation of a MRSA strain with MIC of vancomycinor =2 mg/l is more frequent in the nosocomial-acquired bacteremia episodes, in the clinical practice, it is not a useful predictive parameter because the frequency of isolation of these strains in the community is also high.
- Published
- 2008
33. CO2 chemisorption to characterize calcium catalysts in carbon gasification reactions
- Author
-
Angel Linares-Solano, C. Salinas-Martínez de Lecea, and M. Almela-Alarcon
- Subjects
chemistry ,Chemisorption ,Inorganic chemistry ,chemistry.chemical_element ,Physical and Theoretical Chemistry ,Calcium ,Carbon ,Catalysis - Abstract
CO2 chemisorption, at different temperatures, has been studied in CaO and in the CaO-carbon system by means of simultaneous TG-DTA, MS, and XRD techniques. As a whole the different techniques used show that CO2 chemisorbs in an irreversible manner and is mainly restricted to the surface of the CaO particles, provided that the chemisorption temperature is lower than 573 K. CO2 chemisorption at 573 K can be used as a tool to measure the external surface area of CaO particles. Selective CO2 chemisorption at 573 K has been applied to the CaO-carbon system in the field of catalytic carbon gasification. Several examples are given to show the usefulness of the catalyst surface area determined by CO2 chemisorption in interpreting the catalytic activity of calcium in carbon gasification.
- Published
- 1990
- Full Text
- View/download PDF
34. Calcium-catalysed carbon gasification in CO2 and steam
- Author
-
Angel Linares-Solano, M. Almela-Alarcon, and Concepción Salinas-Martínez de Lecea
- Subjects
chemistry.chemical_classification ,General Chemical Engineering ,Organic Chemistry ,Inorganic chemistry ,Energy Engineering and Power Technology ,chemistry.chemical_element ,Polymer ,Calcium ,Isothermal process ,Catalysis ,Fuel Technology ,chemistry ,Chemisorption ,Particle size ,Dispersion (chemistry) ,Carbon - Abstract
Isothermal CO 2 (0.1 MPa) and steam (19.7 KPa) reactivities on pure polymer carbons have been studied at different temperatures as a function of their calcium contents. Ion-exchange and impregnation methods have been used to load the carbons from calcium acetate solutions. Calcium appears to be a very active catalyst for both reactions, its effectivity being much higher in CO 2 than in steam. Reactivities in both atmospheres increase linearly with Ca content up to a loading saturation level (LSL) of about 4 wt%. For comparable calcium loading, the catalyst addition method, ion-exchange or impregnation, does not produce any significant difference. Selective CO 2 chemisorption has been used to determine the Ca atoms on the surface of the catalyst (and hence its external surface area or dispersion) as functions of both the calcium loading and the preparation method. The results obtained show that CO 2 chemisorption is much more suitable than XRD. This allows interpretation of the catalytic activity of Ca in the carbon-gas reactions. Briefly, gasification rates are related to the amount of CO 2 chemisorbed. The different catalytic behaviour of calcium catalyst above and below the LSL has been interpreted as being due to catalyst dispersion conditioned by carbon carboxyl groups. Only the exchanged calcium has a catalytic activity, whereas the excess calcium has low dispersion, its mean particle size increases considerably, and does not have additional catalytic activity.
- Published
- 1990
- Full Text
- View/download PDF
35. Prospective assessment of the role of antibiotic prophylaxis in ERCP
- Author
-
J, Llach, J M, Bordas, M, Almela, M, Pellisé, A, Mata, M, Soria, G, Fernández-Esparrach, A, Ginès, J I, Elizalde, F, Feu, and J M, Piqué
- Subjects
Cholangiopancreatography, Endoscopic Retrograde ,Male ,Cholangitis ,Clindamycin ,Incidence ,Bacteremia ,Antibiotic Prophylaxis ,Middle Aged ,Anti-Bacterial Agents ,Treatment Outcome ,Humans ,Female ,Gentamicins ,Aged - Abstract
Despite the existence of published recommendations, various studies of antibiotic prophylaxis have reached conflicting conclusions, and controversy exists regarding the role of antibiotic prophylaxis in ERCP. The aim of this study was to analyze the efficacy of the intramuscular administration of clindamicine and gentamicine before ERCP.Sixty-one consecutive patients referred for ERCP were prospectively randomized to receive either clindamicine 600mg and gentamicine 80mg, both intramuscularly one hour before the ERCP (group I; 31 patients) or not (group II; 30 patients). Two blood samples were obtained from every patient (just before endoscopy and within 5 minutes of withdrawal of the endoscope) and were incubated for 7 days and examined daily for growth of bacteria. Patients were closely monitored for 7 days after endoscopy to detect the development of infectious complications.Only 7 cultures from 7 patients were positive. Four were obtained post-ERCP (two patients in group I and two in group II) and the remaining three before endoscopy. The post-ERCP isolated bacteria were: Streptococcus mitis, Peptoestreptococcus anaerobious, Moraxella spp and Escherichia coli. Two patients, one from each group, developed post-ERCP cholangitis that were solved with medical treatment.Our findings indicate that ERCP induce bacteremia in a small group of patients and suggest that prophylactic administration of clindamicine plus gentamicine does not reduce the incidence of bacteremia and cholangitis, and do not support the routine use of prophylactic antibiotics prior to ERCP.
- Published
- 2006
36. [Cytokines value as a sepsis and mortality predictor in elderly patients with fever]
- Author
-
L, Martí, A, Moreno, X, Filella, J L, Marín, M, Almela, N, Benito, M, Sánchez, and J M, Gatell
- Subjects
Male ,Fever ,Interleukin-6 ,Tumor Necrosis Factor-alpha ,Age Factors ,Humans ,Bacteremia ,Female ,Prospective Studies ,Biomarkers ,Aged ,Interleukin-1 - Abstract
Proinflammatory cytokines (IL-1beta, IL-6, TNF-alpha) are excellent predictive factors of tissue damage, inflammation and infection. However, there is not sufficient data about their usefulness in elderly patients with acute septic pathology. Our objective was to identify the cytokines related to bacteremia and those that predicted a bad prognosis in elderly patients.Prospective study carried out during 1999. Patients aged= 60 years with temperature= 38 C admitted to the emergency ward. We determined IL-1beta, IL-6, TNF-alpha and C-reactive protein (CRP); cultures were done according to the infectious source. On the 4th day, cytokines and CRP were recorded again. The follow-up was completed until cure or death.50 patients were included (29 males). Median age was 75.6 (SD: 8.98). The etiology was infectious in 44 (88%): respiratory in 29 (66%), urinary in 8 (18%) and other sources in 7. Thirteen patients had bacteremia (32%): Escherichia coli (4), Streptococcus pneumoniae (5) and others (4). Ten patients died (20%). Median values on admission were CRP : 6.67 mg/dl (NV 0.8), TNF-alpha: 29 pg/ml (NV 0-20), IL-1beta: 7 pg/ml (NV 15) and IL-6: 121 pg/ml (NV 5). 4th day values were: 4.23 mg/dl, 22 pg/ml, 1 pg/ml and 41 pg/ml, respectively. The levels of IL-1b in the 2nd determination were significantly lower in females (p = 0.019). Initial TNF-alpha (p = 0.033), IL-1beta (p = 0.013) and IL-6 (p = 0.031) values were significantly higher in bacteremia patients. IL-6 values on the 4th day were higher in patients who died (p = 0.06). In patients who died, IL-6 levels were higher in the 2nd determination (p = 0.09).Median values of all cytokines were higher in the bacteremia population. Patients who died showed higher levels of IL-6 on the 4th day.
- Published
- 2003
37. [Left to right shunt for congenital coronary arterio-venous fistulas]
- Author
-
P, Baello, B, Sevilla, I, Roldán, V, Mora, M, Almela, and A, Salvador
- Subjects
Male ,Arteriovenous Shunt, Surgical ,Arteriovenous Fistula ,Humans ,Coronary Disease ,Child ,Ultrasonography - Abstract
Congenital coronary artery fistulas are rare malformations that may evolve to pulmonary hypertension, heart failure and myocardial ischemia, although some may close spontaneously. Complications such as endocarditis, rupture, aneurysm or thrombosis may also be observed. Most patients are asymptomatic and the fistulas are usually detected by doppler echocardiography and angiography. We report the case of an asymptomatic 10-year-old male who was submitted because he of a heart murmur, and three coronary fistulas were diagnosed. Two originated in the left coronary artery draining into the right ventricle and the other origin was in the right coronary artery draining into the pulmonary artery trunk.
- Published
- 2001
38. In vitro activities of 22 antimicrobial agents against Listeria monocytogenes strains isolated in Barcelona, Spain. The Collaborative Study Group of Listeriosis of Barcelona
- Author
-
F, Marco, M, Almela, J, Nolla-Salas, P, Coll, I, Gasser, M D, Ferrer, and M, de Simon
- Subjects
Spain ,Humans ,Drug Resistance, Microbial ,Listeriosis ,Microbial Sensitivity Tests ,Listeria monocytogenes ,Anti-Bacterial Agents - Abstract
The in vitro activity of 22 antimicrobial agents against 82 human Listeria monocytogenes strains isolated in Barcelona from 1994 to 1998 was determined. Ampicillin and gentamicin showed good in vitro activity against all strains (MIC90: 1 andor = 0.25 microg/ml, respectively). No resistance to rifampin or co-trimoxazole was detected and only one strain was resistant to tetracycline. Of the nine fluoroquinolones tested, clinafloxacin and gemifloxacin were the most active compounds (MIC90: 0.12 and 0.25 microg/ml, respectively). No increasing MICs values were observed during the five-year period.
- Published
- 2001
39. Reply
- Author
-
A. Soriano, J. A. Martinez, J. Mensa, F. Marco, M. Almela, A. Moreno-Martinez, F. Sanchez, I. Munoz, M. T. Jimenez de Anta, and E. Soriano
- Subjects
Microbiology (medical) ,Infectious Diseases - Published
- 2000
40. [Bacteremia and meningitis caused by Yersinia spp]
- Author
-
J, Robert, A, Moreno, J A, Martínez, M, Almela, M T, Jiménez de Anta, and E, Soriano
- Subjects
Male ,Yersinia Infections ,Humans ,Bacteremia ,Aged ,Meningitis, Bacterial - Abstract
Yersinia spp infection in human people are increasing attention last thirty years. We have reviewed the bacteremia in our hospital last five years. Three episodes were Yersinia spp bacteremia. Presence of disease or predisponent therapy were present in most of episodes. All patients were more than seventy years old. The septic metastasis were present in all the cases: one with meningitis, other with liver abscess and one with septic arthritis. We have documented a good clinical evolution, though the mortality in different reports is around 50%. The election therapy for all episodes were cephalosporins, and in two cases we added quinolones.
- Published
- 2000
41. Estrés y cambios cognitivos asociados al envejecimiento
- Author
-
V., HIDALGO, primary, C., VILLADA, additional, M.M., PULOPULOS, additional, M., ALMELA, additional, and A., SALVADOR, additional
- Published
- 2013
- Full Text
- View/download PDF
42. [Erythromycin-sensitive Streptococcus pyogenes]
- Author
-
F, Marco, J, Mensa, M, Almela, and M T, Jiménez
- Subjects
Streptococcus pyogenes ,Microbial Sensitivity Tests ,Erythromycin - Published
- 1994
43. Lipoprotein (a) and other risk factors in patients with non-insulin-dependent diabetes mellitus
- Author
-
M L, Martínez-Triguero, A, Salvador, M J, Samper, M, Almela, L, Vega, A, Mora, and V, Martínez-Diago
- Subjects
Adult ,Glycated Hemoglobin ,Male ,Diabetes Mellitus, Type 2 ,Arteriosclerosis ,Cardiovascular Diseases ,Risk Factors ,Humans ,Female ,Middle Aged ,Aged ,Lipoprotein(a) - Abstract
Studies have established a relationship between lipoprotein (a) [Lp(a)] levels and cardiovascular disease, but few have studied Lp(a) in patients with non-insulin-dependent diabetes mellitus (NIDDM).We determined Lp(a) concentrations, levels of glycated hemoglobin, and the personal and family history of atherosclerosis in 88 patients with NIDDM (53 men and 35 women; age, 33-70 years) and 90 age- and sex-matched controls. Twenty-three patients with NIDDM had cardiovascular disease (CVD group) and 65 did not (non-CVD group).Lp(a) levels were higher in CVD than non-CVD patients (P0.01). Triglyceride levels negatively correlated with Lp(a) (r = -0.51, P0.05), independently of the metabolic control of diabetes. Patients with poor metabolic control (glycated hemoglobin7.5%) had higher Lp(a) levels than the control group (P0.05). Lp(a) levels were higher than 0.30 milligram in 11% of patients without CVD and 55% of those with CVD (P0.05). Cluster analysis showed that Lp(a), as well as total cholesterol, triglycerides, apolipoprotein B100, and age were independently related to CVD in patients with NIDDM (P0.001 for triglycerides and P0.05 for the other variables).Lp(a) levels can be considered an independent risk factor for the development of atherosclerosis in NIDDM.
- Published
- 1994
44. 138 episodes of bacteremia or fungemia in patients with solid organ (renal or hepatic) transplantation
- Author
-
A, Moreno, J, Mensa, M, Almela, J, Vilardell, M, Navasa, J, Claramonte, A, Cruceta, R, Serrano, J C, García-Valdecasas, and E, Soriano
- Subjects
Incidence ,Humans ,Bacteremia ,Prospective Studies ,Fungemia ,Kidney Transplantation ,Liver Transplantation - Abstract
To study the bacteremias and fungemias of the patients with solid organ transplantation (kidney or liver) and analyze the differences according to the type of graft.A prospective study included in a control program of bacteremias of a 1000-bed hospital and a follow up study of the infections of the patients who had undergone kidney transplantation (KT) (1985-1991) and liver transplantation (LT) (1988-1991) were carried out.One hundred thirty-one bacteremias and 5 fungemias, 75 in 62 patients with KT out of a total of 568 transplantations (11%) and 63 out of 54 patients with LT out of a total of 185 transplantations (29%) were identified. The prevalence of bacteremia in LT was greater (p0.001). The origin was nosocomial in 95% in LT and 70% in KT (p0.001). Around 50% of the bacteremias occurred during the first month post LT and KT. The microorganisms isolated were: Staphylococcus sp. (21 in KT and 30 in LT), with greater incidence in LT (p0.05); Enterococcus sp. (9 and 5, respectively), enterobacterias (12 and 12, respectively), Pseudomonas sp. (14 and 6, respectively), Candida sp. (2 and 3, respectively) with similar rates in both transplants. The origin of bacteremia was; renal and urinary tract, most frequent in KT (21 and 2 respectively) (p = 0.001). The origin of bacteremia was: renal and urinary tract, most frequent in KT (21 and 2 respectively) (p0.001), intraabdominal and biliary tract, most frequent in LT (4 and 14, respectively) (p = 0.007); intravenous catheter, most frequent in LT (16 and 24 respectively) (p0.05); lung, most frequent in LT although without statistical significance (3 and 8, respectively), (p = NS), and finally, surgical wound (4 and 1, respectively) (p = NS). Seventeen patients died (14 with LT and 3 with KT).The incidence of bacteremia and the mortality related, was greater in LT than that observed in KT. The most frequent origin in KT was the kidney and urinary tract and the biliary and intraabdominal organs and the intravenous catheter were most prevalent in liver transplants. Staphylococcus sp was the most frequent germ in both types of transplantation and polymicrobian infection in liver transplants. Gram-negative germs caused higher mortality in liver transplantation.
- Published
- 1994
45. Incidence of listeriosis in Barcelona, Spain, in 1990. The Collaborative Study Group of Listeriosis of Barcelona
- Author
-
J, Nolla-Salas, J M, Antó, M, Almela, P, Coll, I, Gasser, and A, Plasencia
- Subjects
Adult ,Aged, 80 and over ,Male ,Time Factors ,Adolescent ,Incidence ,Middle Aged ,Immunocompromised Host ,Spain ,Humans ,Female ,Listeriosis ,Seasons ,Aged - Abstract
A population-based register of cases of listeriosis admitted to acute-care hospitals has been established in Barcelona, Spain, in order to estimate the basal incidence of sporadic cases and to facilitate epidemiological surveillance of potential epidemics. Eleven acute-care hospitals reported all cases of listeriosis to a central unit following a standardized protocol. During 1990, 31 patients with listeriosis were identified, 18 of whom were residents of the city, resulting in an annual incidence of 10.95 cases per million inhabitants. Twelve of the 31 cases occurred in the period from July to September 1990, ten of them being community-acquired. The incidence of listeriosis was higher in elderly (or = 65 years) and immunosuppressed persons. Forty-two percent of the cases were considered to be nosocomial infections. The overall mortality rate was 51.6%. The incidence of listeriosis in the present study is one of the highest reported in the literature. A high sensitivity of the reporting system with good case identification techniques, or demographic and environmental characteristics related to Listeria monocytogenes infection in our area, might be possible reasons for this geographic variation.
- Published
- 1993
46. [Staphylococcus aureus bacteremia related to intravenous catheters]
- Author
-
R, Serrano-Heranz, J, Mensa, M, Almela, A, Cruceta, A, Moreno, F, Marco, A, Trilla, M T, Jiménez de Anta, and E, Soriano
- Subjects
Adult ,Male ,Cross Infection ,Staphylococcus aureus ,Bacteremia ,Middle Aged ,Staphylococcal Infections ,Prognosis ,Equipment Contamination ,Humans ,Female ,Methicillin Resistance ,Prospective Studies ,Aged - Published
- 1992
47. Induced Porosity in Activated Carbons by Catalytic Activation
- Author
-
MaJ. Mu≁Toz-Guillena, Angel Linares-Solano, MaJ. Illán-Gómez, M. Almela-Alarcon, and C. Salinas-Martínez de Lecea
- Subjects
Pore size ,chemistry.chemical_element ,Calcium ,Catalysis ,Adsorption ,Volume (thermodynamics) ,chemistry ,Chemical engineering ,medicine ,Organic chemistry ,Porosity ,Carbon ,Activated carbon ,medicine.drug - Abstract
Two carbon precursors with very different initial pore size distributions (from almond shells and phenolformaldehyde polymer resin) have been activated in CO 2 and steam. Catalyzed and uncatalyzed activations have been compared using calcium as catalyst. The addition of a catalyst to the carbon activation process influences both the gasification rate and the adsorption capacity of the activated carbon allowing to reduce reaction temperature and to select tailoring of the activated carbon pore size distribution. Total pore volume increases in both carbon series with the extent of burn-off. Catalytic activation in CO 2 produces, in respect to the uncatalyzed process, a remarkable development of the mesoporosity and, as a result, a much wider pore size distribution is obtained. The effect of calcium in the steam activation is much less noticeable.
- Published
- 1991
- Full Text
- View/download PDF
48. Therapeutic Efficacy of the Combination of Aztreonam with Cefotaxime in the Treatment of Severe Nosocomial Pneumonia
- Author
-
Agusti Vidal, M. Almela, Robert Rodriguez-Roisin, E. Rabinad, R. de Celts, A. Torres, R. Deulofeu, and F. Marco
- Subjects
medicine.medical_specialty ,Cefotaxime ,medicine.drug_class ,Antibiotics ,Aztreonam ,medicine.disease_cause ,Gastroenterology ,Microbiology ,chemistry.chemical_compound ,Internal medicine ,Drug Discovery ,medicine ,Pharmacology (medical) ,Candida albicans ,Pharmacology ,biology ,Pseudomonas aeruginosa ,business.industry ,General Medicine ,biology.organism_classification ,medicine.disease ,Pneumonia ,Infectious Diseases ,Oncology ,chemistry ,Amikacin ,Acinetobacter calcoaceticus ,business ,medicine.drug - Abstract
The combination aztreonam + cefotaxime (AZ + CE) was compared to amikacin + cefotaxime (AM + CE) in the treatment of nosocomial pneumonia acquired at the intensive-care unit. This study included a total of 33 patients fulfilling criteria for nosocomial pneumonia. 16 of them were randomly allocated to the AZ + CE group and 17 to the AM + CE group. The empirical treatment was effective for 78% of AZ + CE cases and 92% of AM + CE cases (p = NS). Clinical cure was observed in 77% of cases (10 out of 13 evaluable) in the AZ group and in 75% of the group treated with AM (12 cases out of 16 evaluable; p = NS). In the evaluable cases, treatment failure was associated with injections due to the following organisms: Acinetobacter calcoaceticus (1) and Pseudomonas aeruginosa (1) in the AZ group and A. calcoaceticus (1) in the AM group. Superinfections were observed only in the AM group P. aeruginosa, A. calcoaceticus, Streptococcus viridans, Candida albicans, Aspergillusfumigatus and Serratiamar-cescens. Both the peak and through serum concentrations of AZ and AM were maintained within normal ranges. Finally, an impairment of renal tubular function was observed in the group of patients treated with AM, as measured by urinary levels of N-ace-tyl-β-D-glucosaminidase and leucine aminopeptidase sequentially during the treatment. These changes in renal functions alterations mentioned were not observed in the AZ group. It is concluded that the AZ + CE combination is an effective empirical and active antibiotic treatment against severe nosocomial pneumonia. Aztreonam has no renal toxicity, which is an advantage to take into account in patients with altered renal function.
- Published
- 1989
- Full Text
- View/download PDF
49. Contents, Supplement 1, 1989
- Author
-
J.R. Rodriguez, A. Bosch-Perez, R. Deulofeu, A. Albertazzi, B.L. Wiedermann, R. de Celts, E. Rabinad, G. Salvia, P Ana Lucia Castrillón de, P. Zucchelli, Agusti Vidal, L. Ventriglia, Norman Harry, Arcangel Arango, G. Villa, M.D.V. Martino, Hugo Trujillo, R. Dionigi, N. Mozzillo, L.M.J. Mimica, I.M. Mimica, T. Lotti, Atef M. Shibl, V. Cortecchia, V. Marco, A.H. Ishag, P.A. Ayroza-Galvão, A. Constantopoulos, H. Loupa, F. Marco, N. Moledina, R. Rodriguez-Roisin, M. Fusaroli, M. Bonadio, G. Papoulias, W.J. Rodriguez, V. Car, Felipe Restrepo, Z. Schoss-Videnšek, C.R. Rivera-Vazquez, L. Thomaidou, J. Feris, Guillermo Benitez, Olavo Soares de Souza, M. Santos, S. Schönwald, B. Krznar, T.M. Milstein-Kuschnaroff, J.P. Puig, M. Sasdelli, Marcos F. Moraes, M. Almela, C.H. Ramirez-Ronda, S. Maassen, N.J.F. Cavalcante, R. Lorenco, A. Torres, Dario Birolini, S.P. Barbosa, S. Saavedra, S. Ahmad, M. Gobernado, W.N. Khan, L. Miano, S.M. Durgham, R Gloria Isabel Mejia de, and A. Martelli
- Subjects
Pharmacology ,Infectious Diseases ,Oncology ,Traditional medicine ,Drug Discovery ,Immunology ,Pharmacology (medical) ,General Medicine ,Biology - Published
- 1989
- Full Text
- View/download PDF
50. ‘Anomalous’ increase in CO2 reactivity, relative to steam and air on acid treatment of coals
- Author
-
Francisco Rodríguez-Reinoso, Angel Linares-Solano, Concepción Salinas-Martínez de Lecea, and M. Almela-Alarcon
- Subjects
Bituminous coal ,business.industry ,Chemistry ,General Chemical Engineering ,Organic Chemistry ,Inorganic chemistry ,geology.rock_type ,geology ,Energy Engineering and Power Technology ,complex mixtures ,Demineralization ,Co2 reactivity ,Fuel Technology ,Acid treatment ,Reactivity (chemistry) ,Coal ,business ,Mineral matter - Abstract
The reactivities in steam, CO 2 and air of two high-ash Spanish coal chars (from a semi-anthracite and a high volatile bituminous coal) and the effects of previous acid demineralization on these reactivities have been studied. The different acid treatments used increased the reactivities of both chars in the three atmospheres, the increase being much larger for samples treated with HCl + HF , especially in the reaction with CO 2 . This apparently anomalous increase in CO 2 reactivity (relative to steam and air) for both chars, which can also be observed in published results, seems to be mainly related to the HF treatment and the remaining mineral matter, as deduced from a study undertaken on two very low-ash carbons.
- Published
- 1986
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.